Davids, Matthew
eCommons Login: MSD15
first name: Matthew
last name: Davids
coauthor of: Brown, Jennifer
coauthor of: Ryan, Christine
coauthor of: Ahn, Inhye
coauthor of: Chong, Stephen
coauthor of: Crombie, Jennifer
full name: Matthew Steven Davids, M.D.
has faculty rank: Associate Professor
has network: selected publications
has network: research areas
has network: coauthor of
has network: similar to
latitude: 42.33789600000000
longitude: -71.10724930000000
Person ID: 74207
person in primary position: Associate Professor of Medicine
physical neighbor: DeAngelo, Daniel
physical neighbor: Jacobson, Caron
physical neighbor: Li, Shuqiang
physical neighbor: Morgans, Alicia
physical neighbor: Polyak, Kornelia
similar to: Brown, Jennifer
similar to: Ghia, Paolo
similar to: Wu, Catherine
similar to: Castillo, Jorge
similar to: Ahn, Inhye
type: Agent
type: Person
selected publications: Authorship 1834475
selected publications: Authorship 1831495
selected publications: Authorship 1833924
selected publications: Authorship 1834840
selected publications: Authorship 1848072
selected publications: Authorship 1813802
selected publications: Authorship 1813993
selected publications: Authorship 1829889
selected publications: Authorship 1794409
selected publications: Authorship 1813423
selected publications: Authorship 1815337
selected publications: Authorship 1793503
selected publications: Authorship 1817725
selected publications: Authorship 1816365
selected publications: Authorship 1792689
selected publications: Authorship 1740119
selected publications: Authorship 1846083
selected publications: Authorship 1846069
selected publications: Authorship 1741174
selected publications: Authorship 1824990
selected publications: Authorship 1749357
selected publications: Authorship 1783000
selected publications: Authorship 1745210
selected publications: Authorship 1808945
selected publications: Authorship 1825942
selected publications: Authorship 1745974
selected publications: Authorship 1750875
selected publications: Authorship 1731064
selected publications: Authorship 1716366
selected publications: Authorship 1735956
selected publications: Authorship 1722503
selected publications: Authorship 1718601
selected publications: Authorship 1678034
selected publications: Authorship 1694156
selected publications: Authorship 1716085
selected publications: Authorship 1700879
selected publications: Authorship 1715041
selected publications: Authorship 1708362
selected publications: Authorship 1702186
selected publications: Authorship 1823809
selected publications: Authorship 1650717
selected publications: Authorship 1695401
selected publications: Authorship 1664169
selected publications: Authorship 1646740
selected publications: Authorship 1663729
selected publications: Authorship 1641315
selected publications: Authorship 1608475
selected publications: Authorship 1636895
selected publications: Authorship 1626070

eCommons Login
tag name: catalyst:eCommonsLogin
type: DatatypeProperty

coauthor of
tag name: prns:coAuthorOf
type: ObjectProperty

end date
tag name: prns:endDate
type: DatatypeProperty

Faculty Rank
type: Class

full name
tag name: prns:fullName
type: DatatypeProperty

author list
tag name: prns:hasAuthorList
type: DatatypeProperty

has faculty rank
tag name: prns:hasFacultyRank
type: ObjectProperty

has network
tag name: prns:hasNetwork
type: ObjectProperty

published in
tag name: prns:hasPublicationVenue
type: DatatypeProperty

information resource reference
tag name: prns:informationResourceReference
type: DatatypeProperty

is primary position
tag name: prns:isPrimaryPosition
type: DatatypeProperty

latitude
tag name: prns:latitude
type: DatatypeProperty

longitude
tag name: prns:longitude
type: DatatypeProperty

photo
tag name: prns:mainImage
type: ObjectProperty

maximum weight
tag name: prns:maxWeight
type: DatatypeProperty

journal title abbreviation
tag name: prns:medlineTA
type: DatatypeProperty

MeSH DescriptorUI
tag name: prns:meshDescriptorUI
type: DatatypeProperty

MeSH semantic group name
tag name: prns:meshSemanticGroupName
type: DatatypeProperty

minimum weight
tag name: prns:minWeight
type: DatatypeProperty

number of authors
tag name: prns:numberOfAuthors
type: DatatypeProperty

number of connections
tag name: prns:numberOfConnections
type: DatatypeProperty

number of publications
tag name: prns:numberOfPublications
type: DatatypeProperty

Person ID
tag name: prns:personId
type: DatatypeProperty

person in primary position
tag name: prns:personInPrimaryPosition
type: ObjectProperty

physical neighbor
tag name: prns:physicalNeighborOf
type: ObjectProperty

position in department
tag name: prns:positionInDepartment
type: ObjectProperty

position in division
tag name: prns:positionInDivision
type: ObjectProperty

predicate node
tag name: prns:predicateNode
type: ObjectProperty

principal investigator name
tag name: prns:principalInvestigatorName
type: DatatypeProperty

publication date
tag name: prns:publicationDate
type: DatatypeProperty

similar to
tag name: prns:similarTo
type: ObjectProperty

sort order
tag name: prns:sortOrder
type: DatatypeProperty

start date
tag name: prns:startDate
type: DatatypeProperty

uniqueness weight
tag name: prns:uniquenessWeight
type: DatatypeProperty

year
tag name: prns:year
type: DatatypeProperty

Academic Article
type: Class

Article
type: Class

Document
type: Class

PubMed Identifier
tag name: bibo:pmid
type: DatatypeProperty

Address
type: Class

address line 1
tag name: vivo:address1
type: DatatypeProperty

address line 2
tag name: vivo:address2
type: DatatypeProperty

address line 3
tag name: vivo:address3
type: DatatypeProperty

city
tag name: vivo:addressCity
type: DatatypeProperty
type: FunctionalProperty

postal code
tag name: vivo:addressPostalCode
type: DatatypeProperty
type: FunctionalProperty

state or province
tag name: vivo:addressState
type: DatatypeProperty
type: FunctionalProperty

selected publications
tag name: vivo:authorInAuthorship
type: ObjectProperty

author rank in publication
tag name: vivo:authorRank
type: DatatypeProperty
type: FunctionalProperty

Authorship
type: Class

Department
type: Class

Division
type: Class

Grant
type: Class

research areas
tag name: vivo:hasResearchArea
type: ObjectProperty

research activities
tag name: vivo:hasResearcherRole
type: ObjectProperty

HR job title
tag name: vivo:hrJobTitle
type: DatatypeProperty

Information Resource
type: Class

linked author
tag name: vivo:linkedAuthor
type: ObjectProperty

linked information resource
tag name: vivo:linkedInformationResource
type: ObjectProperty

mailing address
tag name: vivo:mailingAddress
type: ObjectProperty

middle name or initial
tag name: vivo:middleName
type: DatatypeProperty
type: FunctionalProperty

positions
tag name: vivo:personInPosition
type: ObjectProperty

phone
tag name: vivo:phoneNumber
type: DatatypeProperty

Position
type: Class

position in organization
tag name: vivo:positionInOrganization
type: ObjectProperty

preferred title
tag name: vivo:preferredTitle
type: DatatypeProperty
type: FunctionalProperty

Researcher Role
type: Class

researcher role of
tag name: vivo:researcherRoleOf
type: ObjectProperty

contributes to
tag name: vivo:roleContributesTo
type: ObjectProperty

sponsor award id
tag name: vivo:sponsorAwardId
type: DatatypeProperty
type: FunctionalProperty

predicate
tag name: rdf:predicate
type: ObjectProperty

type
tag name: rdf:type
type: ObjectProperty

label
tag name: rdfs:label
type: DatatypeProperty

Concept
type: Class

Agent
type: Class

first name
tag name: foaf:firstName
type: DatatypeProperty
type: FunctionalProperty

last name
tag name: foaf:lastName
type: DatatypeProperty
type: FunctionalProperty

Organization
type: Class

Person
type: Class

Authorship 1047747
type: Authorship
author rank in publication: 7
linked author: Davids, Matthew
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/100207667

Authorship 1050045
type: Authorship
author rank in publication: 4
linked author: Davids, Matthew
linked information resource: Risk of hepatitis B virus reactivation in patients treated with ibrutinib.

https://connects.catalyst.harvard.edu/Profiles/profile/100207667
PubMed Identifier: 29415595
author list: Flowers CR, Nabhan C, Kay NE, Mato A, Lamanna N, Farber CM, Davids MS, Kiselev P, Swern AS, Sullivan K, Flick ED, Sharman JP
published in: Leukemia & lymphoma
information resource reference: Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect® CLL cohort study. Leuk Lymphoma. 2018 10; 59(10):2327-2335.
journal title abbreviation: Leuk Lymphoma
publication date: 2018-02-07T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect® CLL cohort study.

Risk of hepatitis B virus reactivation in patients treated with ibrutinib.
PubMed Identifier: 29490923
author list: Hammond SP, Chen K, Pandit A, Davids MS, Issa NC, Marty FM
published in: Blood
information resource reference: Risk of hepatitis B virus reactivation in patients treated with ibrutinib. Blood. 2018 04 26; 131(17):1987-1989.
journal title abbreviation: Blood
publication date: 2018-02-28T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1059431
type: Authorship
author rank in publication: 2
linked author: Davids, Matthew
linked information resource: Review of targeted therapy in chronic lymphocytic leukemia: what a radiologist needs to know about CT interpretation.

Review of targeted therapy in chronic lymphocytic leukemia: what a radiologist needs to know about CT interpretation.
PubMed Identifier: 29669600
author list: Gosangi B, Davids M, Somarouthu B, Alessandrino F, Giardino A, Ramaiya N, Krajewski K
published in: Cancer imaging : the official publication of the International Cancer Imaging Society
information resource reference: Review of targeted therapy in chronic lymphocytic leukemia: what a radiologist needs to know about CT interpretation. Cancer Imaging. 2018 Apr 18; 18(1):13.
journal title abbreviation: Cancer Imaging
publication date: 2018-04-18T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1062599
type: Authorship
author rank in publication: 13
linked author: Davids, Matthew
linked information resource: Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.

Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.
PubMed Identifier: 29715056
author list: Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, Jurczak W, Mulligan SP, Schuh A, Assouline S, Wendtner CM, Roberts AW, Davids MS, Bloehdorn J, Munir T, Böttcher S, Zhou L, Salem AH, Desai M, Chyla B, Arzt J, Kim SY, Verdugo M, Gordon G, Hallek M, Wierda WG
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. J Clin Oncol. 2018 07 01; 36(19):1973-1980.
journal title abbreviation: J Clin Oncol
publication date: 2018-05-01T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 10666
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: Phosphoinositide 3'-kinase inhibition in chronic lymphocytic leukemia.

Authorship 1073322
type: Authorship
author rank in publication: 15
linked author: Davids, Matthew
linked information resource: Statins enhance efficacy of venetoclax in blood cancers.

Authorship 1072125
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.

Statins enhance efficacy of venetoclax in blood cancers.
PubMed Identifier: 29899021
author list: Lee JS, Roberts A, Juarez D, Vo TT, Bhatt S, Herzog LO, Mallya S, Bellin RJ, Agarwal SK, Salem AH, Xu T, Jia J, Li L, Hanna JR, Davids MS, Fleischman AG, O'Brien S, Lam LT, Leverson JD, Letai A, Schatz JH, Fruman DA
published in: Science translational medicine
information resource reference: Statins enhance efficacy of venetoclax in blood cancers. Sci Transl Med. 2018 06 13; 10(445).
journal title abbreviation: Sci Transl Med
publication date: 2018-06-13T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.
PubMed Identifier: 29895707
author list: Davids MS, Hallek M, Wierda W, Roberts AW, Stilgenbauer S, Jones JA, Gerecitano JF, Kim SY, Potluri J, Busman T, Best A, Verdugo ME, Cerri E, Desai M, Hillmen P, Seymour JF
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. Clin Cancer Res. 2018 09 15; 24(18):4371-4379.
journal title abbreviation: Clin Cancer Res
publication date: 2018-06-12T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1079131
type: Authorship
author rank in publication: 3
linked author: Davids, Matthew
linked information resource: The rise of apoptosis: targeting apoptosis in hematologic malignancies.

The rise of apoptosis: targeting apoptosis in hematologic malignancies.
PubMed Identifier: 30012635
author list: Valentin R, Grabow S, Davids MS
published in: Blood
information resource reference: The rise of apoptosis: targeting apoptosis in hematologic malignancies. Blood. 2018 09 20; 132(12):1248-1264.
journal title abbreviation: Blood
publication date: 2018-07-16T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1084176
type: Authorship
author rank in publication: 4
linked author: Davids, Matthew
linked information resource: Isavuconazole for the treatment of invasive fungal disease in patients receiving ibrutinib.

Isavuconazole for the treatment of invasive fungal disease in patients receiving ibrutinib.
PubMed Identifier: 30037292
author list: Cummins KC, Cheng MP, Kubiak DW, Davids MS, Marty FM, Issa NC
published in: Leukemia & lymphoma
information resource reference: Isavuconazole for the treatment of invasive fungal disease in patients receiving ibrutinib. Leuk Lymphoma. 2019 02; 60(2):527-530.
journal title abbreviation: Leuk Lymphoma
publication date: 2018-07-24T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

The molecular pathogenesis of myelodysplastic syndromes.
PubMed Identifier: 20592488
author list: Davids MS, Steensma DP
published in: Cancer biology & therapy
information resource reference: The molecular pathogenesis of myelodysplastic syndromes. Cancer Biol Ther. 2010 Aug 15; 10(4):309-19.
journal title abbreviation: Cancer Biol Ther
publication date: 2010-08-05T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1096609
type: Authorship
author rank in publication: 14
linked author: Davids, Matthew
linked information resource: The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL.

Authorship 1097210
type: Authorship
author rank in publication: 29
linked author: Davids, Matthew
linked information resource: Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies.

Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies.
PubMed Identifier: 30282833
author list: Ten Hacken E, Valentin R, Regis FFD, Sun J, Yin S, Werner L, Deng J, Gruber M, Wong J, Zheng M, Gill AL, Seiler M, Smith P, Thomas M, Buonamici S, Ghia EM, Kim E, Rassenti LZ, Burger JA, Kipps TJ, Meyerson ML, Bachireddy P, Wang L, Reed R, Neuberg D, Carrasco RD, Brooks AN, Letai A, Davids MS, Wu CJ
published in: JCI insight
information resource reference: Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. JCI Insight. 2018 10 04; 3(19).
journal title abbreviation: JCI Insight
publication date: 2018-10-04T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL.
PubMed Identifier: 30287523
author list: Flinn IW, Hillmen P, Montillo M, Nagy Z, Illés Á, Etienne G, Delgado J, Kuss BJ, Tam CS, Gasztonyi Z, Offner F, Lunin S, Bosch F, Davids MS, Lamanna N, Jaeger U, Ghia P, Cymbalista F, Portell CA, Skarbnik AP, Cashen AF, Weaver DT, Kelly VM, Turnbull B, Stilgenbauer S
published in: Blood
information resource reference: The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood. 2018 12 06; 132(23):2446-2455.
journal title abbreviation: Blood
publication date: 2018-10-04T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 122677
type: Authorship
author rank in publication: 6
linked author: Davids, Matthew
linked information resource: Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era.

Authorship 1104682
type: Authorship
author rank in publication: 2
linked author: Davids, Matthew
linked information resource: A new triple threat to CLL.

Authorship 1102375
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/112011876

A new triple threat to CLL.
PubMed Identifier: 30309874
author list: Lampson BL, Davids MS
published in: Blood
information resource reference: A new triple threat to CLL. Blood. 2018 10 11; 132(15):1547-1548.
journal title abbreviation: Blood
publication date: 2018-10-11T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/112011876
PubMed Identifier: 30322319
author list: Davids MS, Kim HT, Yu L, De Maeyer G, McDonough M, Vartanov AR, Langey R, Fernandes SM, Hellman JM, Francoeur K, Arnason J, Jacobsen ED, LaCasce AS, Fisher DC, Brown JR
published in: Leukemia & lymphoma
information resource reference: Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia. Leuk Lymphoma. 2019 05; 60(5):1312-1315.
journal title abbreviation: Leuk Lymphoma
publication date: 2018-10-15T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia.

Authorship 113684
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia.

Authorship 1110147
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma.

Authorship 1110091
type: Authorship
author rank in publication: 4
linked author: Davids, Matthew
linked information resource: Synchronous squamous cell carcinoma and diffuse large B-cell lymphoma of the head and neck: the odd couple.

Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma.
PubMed Identifier: 30359156
author list: Davids MS, von Keudell G, Portell CA, Cohen JB, Fisher DC, Foss F, Roberts AW, Seymour JF, Humerickhouse RA, Tam CS
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma. J Clin Oncol. 2018 Oct 25; JCO1800359.
journal title abbreviation: J Clin Oncol
publication date: 2018-10-25T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Synchronous squamous cell carcinoma and diffuse large B-cell lymphoma of the head and neck: the odd couple.
PubMed Identifier: 30364391
author list: Raldow AC, Brown JG, Chau N, Davids MS, Margalit DN, Tishler RB, Ng A, Schoenfeld JD
published in: BJR case reports
information resource reference: Synchronous squamous cell carcinoma and diffuse large B-cell lymphoma of the head and neck: the odd couple. BJR Case Rep. 2016; 2(1):20150271.
journal title abbreviation: BJR Case Rep
publication date: 2016-01-19T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1116554
type: Authorship
author rank in publication: 3
linked author: Davids, Matthew
linked information resource: Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor.

Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor.
PubMed Identifier: 30478940
author list: Wierda WG, Byrd JC, Davids MS, Furman RR, Cheson BD, Barr PM, Eradat H, Heffner L, Zhou L, Verdugo M, Potluri J, Choi M
published in: British journal of haematology
information resource reference: Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor. Br J Haematol. 2019 06; 185(5):961-966.
journal title abbreviation: Br J Haematol
publication date: 2018-11-27T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1120162
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.

Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
PubMed Identifier: 30558987
author list: Davids MS, Kim HT, Nicotra A, Savell A, Francoeur K, Hellman JM, Bazemore J, Miskin HP, Sportelli P, Stampleman L, Maegawa R, Rueter J, Boruchov AM, Arnason JE, Jacobson CA, Jacobsen ED, Fisher DC, Brown JR
published in: The Lancet. Haematology
information resource reference: Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study. Lancet Haematol. 2019 Jan; 6(1):e38-e47.
journal title abbreviation: Lancet Haematol
publication date: 2018-12-14T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia.
PubMed Identifier: 22955911
author list: Davids MS, Deng J, Wiestner A, Lannutti BJ, Wang L, Wu CJ, Wilson WH, Brown JR, Letai A
published in: Blood
information resource reference: Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. Blood. 2012 Oct 25; 120(17):3501-9.
journal title abbreviation: Blood
publication date: 2012-09-05T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Phosphoinositide 3'-kinase inhibition in chronic lymphocytic leukemia.
PubMed Identifier: 23561476
author list: Davids MS, Brown JR
published in: Hematology/oncology clinics of North America
information resource reference: Phosphoinositide 3'-kinase inhibition in chronic lymphocytic leukemia. Hematol Oncol Clin North Am. 2013 Apr; 27(2):329-39.
journal title abbreviation: Hematol Oncol Clin North Am
publication date: 2013-04-01T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Benzamides
MeSH DescriptorUI: D001549
MeSH semantic group name: Chemicals & Drugs
number of authors: 634
number of publications: 1499
uniqueness weight: 0.632487
type: Concept

Proto-Oncogene Proteins c-bcl-2
MeSH DescriptorUI: D019253
MeSH semantic group name: Chemicals & Drugs
number of authors: 633
number of publications: 1380
uniqueness weight: 0.624143
type: Concept

Antineoplastic Combined Chemotherapy Protocols
MeSH DescriptorUI: D000971
MeSH semantic group name: Procedures
number of authors: 1828
number of publications: 12496
uniqueness weight: 0.217379
type: Concept

Authorship 1144010
type: Authorship
author rank in publication: 3
linked author: Davids, Matthew
linked information resource: Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia.

Authorship 1144598
type: Authorship
author rank in publication: 3
linked author: Davids, Matthew
linked information resource: Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy.

Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia.
PubMed Identifier: 30967392
author list: Lampson BL, Kim HT, Davids MS, Abramson JS, Freedman AS, Jacobson CA, Armand PA, Joyce RM, Arnason JE, Rassenti LZ, Kipps TJ, Fein J, Fernandes SM, Hanna JR, Fisher DC, Brown JR
published in: Blood advances
information resource reference: Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia. Blood Adv. 2019 04 09; 3(7):1167-1174.
journal title abbreviation: Blood Adv
publication date: 2019-04-09T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy.
PubMed Identifier: 30923097
author list: Mato AR, Wierda WG, Davids MS, Cheson BD, Coutre SE, Choi M, Furman RR, Heffner L, Barr PM, Eradat H, Ford SM, Zhou L, Verdugo M, Humerickhouse RA, Potluri J, Byrd JC
published in: Haematologica
information resource reference: Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy. Haematologica. 2019 11; 104(11):2258-2264.
journal title abbreviation: Haematologica
publication date: 2019-03-28T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Leukemia, Lymphocytic, Chronic, B-Cell
MeSH DescriptorUI: D015451
MeSH semantic group name: Disorders
number of authors: 388
number of publications: 1797
uniqueness weight: 0.42854
type: Concept

Authorship 1148962
type: Authorship
author rank in publication: 5
linked author: Davids, Matthew
linked information resource: Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables.

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables.
PubMed Identifier: 31023700
author list: Roberts AW, Ma S, Kipps TJ, Coutre SE, Davids MS, Eichhorst B, Hallek M, Byrd JC, Humphrey K, Zhou L, Chyla B, Nielsen J, Potluri J, Kim SY, Verdugo M, Stilgenbauer S, Wierda WG, Seymour JF
published in: Blood
information resource reference: Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. Blood. 2019 07 11; 134(2):111-122.
journal title abbreviation: Blood
publication date: 2019-04-25T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1149940
type: Authorship
author rank in publication: 2
linked author: Davids, Matthew
linked information resource: Venetoclax: R-CHOP rocket booster?

Authorship 1150705
type: Authorship
author rank in publication: 8
linked author: Davids, Matthew
linked information resource: Psoriasiform eruptions secondary to phosphoinositide 3-kinase inhibition.

Psoriasiform eruptions secondary to phosphoinositide 3-kinase inhibition.
PubMed Identifier: 31049381
author list: Dewan AK, Gupta S, Bach DQ, Jadeja S, Granter S, LaCasce A, Joyce R, Davids MS, Huang V, LeBoeuf NR
published in: JAAD case reports
information resource reference: Psoriasiform eruptions secondary to phosphoinositide 3-kinase inhibition. JAAD Case Rep. 2019 May; 5(5):401-405.
journal title abbreviation: JAAD Case Rep
publication date: 2019-04-20T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Venetoclax: R-CHOP rocket booster?
PubMed Identifier: 31048302
author list: Herbaux C, Davids MS
published in: Blood
information resource reference: Venetoclax: R-CHOP rocket booster? Blood. 2019 05 02; 133(18):1922-1924.
journal title abbreviation: Blood
publication date: 2019-05-02T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Sulfonamides
MeSH DescriptorUI: D013449
MeSH semantic group name: Chemicals & Drugs
number of authors: 960
number of publications: 2122
uniqueness weight: 0.483802
type: Concept

Authorship 1151561
type: Authorship
author rank in publication: 2
linked author: Davids, Matthew
linked information resource: Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia.

Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia.
PubMed Identifier: 31074316
author list: Soumerai JD, Davids MS, Werner L, Fisher DC, Armand P, Amrein PC, Neuberg D, Hochberg EP, Brown JR, Abramson JS
published in: Leukemia & lymphoma
information resource reference: Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2019 12; 60(12):2931-2938.
journal title abbreviation: Leuk Lymphoma
publication date: 2019-05-10T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Medicine
type: Department
type: Organization

Adult Oncology
type: Division
type: Organization

Oncology
type: Division
type: Organization

Dana-Farber Cancer Institute
type: Organization

selected publications
maximum weight: 1
minimum weight: 1
number of connections: 228
predicate node: https://connects.catalyst.harvard.edu/Profiles/profile/113
predicate: selected publications
type: Network

research areas
maximum weight: 21.8088
minimum weight: 0.00356337
number of connections: 459
predicate node: https://connects.catalyst.harvard.edu/Profiles/profile/217
predicate: research areas
type: Network

coauthor of
maximum weight: 14.5849
minimum weight: 0.0237033
number of connections: 143
predicate node: https://connects.catalyst.harvard.edu/Profiles/profile/363
predicate: coauthor of
type: Network

similar to
maximum weight: 1144.74
minimum weight: 47.3018
number of connections: 60
predicate node: https://connects.catalyst.harvard.edu/Profiles/profile/494
predicate: similar to
type: Network

Morgans, Alicia
eCommons Login: AKM28
first name: Alicia
last name: Morgans
full name: Alicia Katherine Morgans, M.D.
has faculty rank: Associate Professor
latitude: 42.33789600000000
longitude: -71.10724930000000
Person ID: 85161
person in primary position: Associate Professor of Medicine
type: Agent
type: Person
preferred title: Associate Professor of Medicine

Li, Shuqiang
first name: Shuqiang
last name: Li
full name: Shuqiang Li, Ph.D.
has faculty rank: Other Faculty
latitude: 42.33789600000000
longitude: -71.10724930000000
Person ID: 8960
person in primary position: Research Associate in Medicine
type: Agent
type: Person
preferred title: Research Associate in Medicine

Crombie, Jennifer
eCommons Login: JLC43
first name: Jennifer
last name: Crombie
full name: Jennifer Leigh Crombie, M.D.
has faculty rank: Assistant Professor
Person ID: 109304
person in primary position: Assistant Professor of Medicine
type: Agent
type: Person
preferred title: Assistant Professor of Medicine

Brown, Jennifer
eCommons Login: JRB4
first name: Jennifer
last name: Brown
full name: Jennifer Ruth Brown, M.D., Ph.D.
has faculty rank: Full Professor
latitude: 42.33789600000000
longitude: -71.10724930000000
Person ID: 35701
person in primary position: Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology
type: Agent
type: Person
preferred title: Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology

DeAngelo, Daniel
eCommons Login: DJD3
first name: Daniel
last name: DeAngelo
full name: Daniel J. DeAngelo, M.D., Ph.D.
has faculty rank: Full Professor
latitude: 42.33789600000000
longitude: -71.10724930000000
Person ID: 50464
person in primary position: Professor of Medicine
type: Agent
type: Person
preferred title: Professor of Medicine

Jacobson, Caron
eCommons Login: CAJ11
first name: Caron
last name: Jacobson
full name: Caron Alyce Jacobson, M.D.
has faculty rank: Associate Professor
latitude: 42.33789600000000
longitude: -71.10724930000000
Person ID: 46233
person in primary position: Associate Professor of Medicine
type: Agent
type: Person
preferred title: Associate Professor of Medicine

Ghia, Paolo
eCommons Login: PG92
first name: Paolo
last name: Ghia
full name: Paolo Ghia, M.D., Ph.D.
has faculty rank: Lecturer
Person ID: 114101
person in primary position: Senior Lecturer on Medicine, Part-time
type: Agent
type: Person
preferred title: Senior Lecturer on Medicine, Part-time

Chong, Stephen
eCommons Login: SJC36
first name: Stephen
last name: Chong
full name: Stephen Jun Fei Chong, Ph.D.
has faculty rank: Fellow or Post Doc
Person ID: 180659
person in primary position: Research Fellow in Medicine
type: Agent
type: Person
preferred title: Research Fellow in Medicine

Wu, Catherine
eCommons Login: CJW1
first name: Catherine
last name: Wu
full name: Catherine Ju-Ying Wu, M.D.
has faculty rank: Full Professor
latitude: 42.33789600000000
longitude: -71.10724930000000
Person ID: 10810
person in primary position: Professor of Medicine
type: Agent
type: Person
preferred title: Professor of Medicine

Authorship 1163259
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.

Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.
PubMed Identifier: 31208944
author list: Davids MS, Brander DM, Kim HT, Tyekucheva S, Bsat J, Savell A, Hellman JM, Bazemore J, Francoeur K, Alencar A, Shune L, Omaira M, Jacobson CA, Armand P, Ng S, Crombie J, LaCasce AS, Arnason J, Hochberg EP, Takvorian RW, Abramson JS, Fisher DC, Brown JR
published in: The Lancet. Haematology
information resource reference: Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2019 Aug; 6(8):e419-e428.
journal title abbreviation: Lancet Haematol
publication date: 2019-06-14T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Polyak, Kornelia
eCommons Login: KP5
first name: Kornelia
last name: Polyak
full name: Kornelia Polyak, M.D., Ph.D.
has faculty rank: Full Professor
latitude: 42.33789600000000
longitude: -71.10724930000000
Person ID: 76355
person in primary position: Professor of Medicine
type: Agent
type: Person
preferred title: Professor of Medicine

Authorship 1168617
type: Authorship
author rank in publication: 4
linked author: Davids, Matthew
linked information resource: Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report.

Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report.
PubMed Identifier: 31253630
author list: Kim HT, Ahn KW, Hu ZH, Davids MS, Volpe VO, Antin JH, Sorror ML, Shadman M, Press O, Pidala J, Hogan W, Negrin R, Devine S, Uberti J, Agura E, Nash R, Mehta J, McGuirk J, Forman S, Langston A, Giralt SA, Perales MA, Battiwalla M, Hale GA, Gale RP, Marks DI, Hamadani M, Ganguly S, Bacher U, Lazarus H, Reshef R, Hildebrandt GC, Inamoto Y, Cahn JY, Solh M, Kharfan-Dabaja MA, Ghosh N, Saad A, Aljurf M, Schouten HC, Hill BT, Pawarode A, Kindwall-Keller T, Saba N, Copelan EA, Nathan S, Beitinjaneh A, Savani BN, Cerny J, Grunwald MR, Yared J, Wirk BM, Nishihori T, Chhabra S, Olsson RF, Bashey A, Gergis U, Popat U, Sobecks R, Alyea E, Saber W, Brown JR
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. Clin Cancer Res. 2019 08 15; 25(16):5143-5155.
journal title abbreviation: Clin Cancer Res
publication date: 2019-06-28T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1173712
type: Authorship
author rank in publication: 5
linked author: Davids, Matthew
linked information resource: Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia.

Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia.
PubMed Identifier: 31292114
author list: Staber PB, Herling M, Bellido M, Jacobsen ED, Davids MS, Kadia TM, Shustov A, Tournilhac O, Bachy E, Zaja F, Porkka K, Hoermann G, Simonitsch-Klupp I, Haferlach C, Kubicek S, Mayerhoefer ME, Hopfinger G, Jaeger U, Dearden C
published in: Blood
information resource reference: Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. Blood. 2019 10 03; 134(14):1132-1143.
journal title abbreviation: Blood
publication date: 2019-07-10T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1193538
type: Authorship
author rank in publication: 19
linked author: Davids, Matthew
linked information resource: Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies.

Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies.
PubMed Identifier: 31543463
author list: Guièze R, Liu VM, Rosebrock D, Jourdain AA, Hernández-Sánchez M, Martinez Zurita A, Sun J, Ten Hacken E, Baranowski K, Thompson PA, Heo JM, Cartun Z, Aygün O, Iorgulescu JB, Zhang W, Notarangelo G, Livitz D, Li S, Davids MS, Biran A, Fernandes SM, Brown JR, Lako A, Ciantra ZB, Lawlor MA, Keskin DB, Udeshi ND, Wierda WG, Livak KJ, Letai AG, Neuberg D, Harper JW, Carr SA, Piccioni F, Ott CJ, Leshchiner I, Johannessen CM, Doench J, Mootha VK, Getz G, Wu CJ
published in: Cancer cell
information resource reference: Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. Cancer Cell. 2019 10 14; 36(4):369-384.e13.
journal title abbreviation: Cancer Cell
publication date: 2019-09-19T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 155268
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: ABT-199: taking dead aim at BCL-2.

Authorship 1204214
type: Authorship
author rank in publication: 16
linked author: Davids, Matthew
linked information resource: Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL).

Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL).
PubMed Identifier: 31723987
author list: Lampson BL, Tyekucheva S, Crombie JL, Kim AI, Merryman RW, Lowney J, Montegaard J, Patterson V, Jacobson CA, Jacobsen ED, LaCasce AS, Arnason JE, Armand P, Fisher DC, Brown JR, Davids MS
published in: Blood
information resource reference: Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL). Blood. 2019 Nov 13; 134(Supplement_1):32.
journal title abbreviation: Blood
publication date: 2019-11-13T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Professor of Medicine
is primary position: true
position in department: Medicine
position in division: Adult Oncology
sort order: 1
type: Position
HR job title: Professor of Medicine
position in organization: Dana-Farber Cancer Institute

Authorship 1208048
type: Authorship
author rank in publication: 2
linked author: Davids, Matthew
linked information resource: BCL-2 Inhibitors, Present and Future.

BCL-2 Inhibitors, Present and Future.
PubMed Identifier: 31764121
author list: Ryan CE, Davids MS
published in: Cancer journal (Sudbury, Mass.)
information resource reference: BCL-2 Inhibitors, Present and Future. Cancer J. 2019 Nov/Dec; 25(6):401-409.
journal title abbreviation: Cancer J
publication date: 2019-11-01T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1214110
type: Authorship
author rank in publication: 4
linked author: Davids, Matthew
linked information resource: Cutaneous eruptions from ibrutinib resembling epidermal growth factor receptor inhibitor-induced dermatologic adverse events.

Cutaneous eruptions from ibrutinib resembling epidermal growth factor receptor inhibitor-induced dermatologic adverse events.
PubMed Identifier: 31870917
author list: Singer S, Tan SY, Dewan AK, Davids M, LaCasce AS, Treon SP, LeBoeuf NR
published in: Journal of the American Academy of Dermatology
information resource reference: Cutaneous eruptions from ibrutinib resembling epidermal growth factor receptor inhibitor-induced dermatologic adverse events. J Am Acad Dermatol. 2023 06; 88(6):1271-1281.
journal title abbreviation: J Am Acad Dermatol
publication date: 2019-12-20T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1220802
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study.

Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study.
PubMed Identifier: 31964785
author list: Davids MS, Kuss BJ, Hillmen P, Montillo M, Moreno C, Essell J, Lamanna N, Nagy Z, Tam CS, Stilgenbauer S, Ghia P, Delgado J, Lustgarten S, Weaver DT, Youssoufian H, Jäger U
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study. Clin Cancer Res. 2020 05 01; 26(9):2096-2103.
journal title abbreviation: Clin Cancer Res
publication date: 2020-01-21T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Breaking through BCL-2 inhibition in CLL.
PubMed Identifier: 32135019
author list: Chong SJF, Davids MS
published in: Blood
information resource reference: Breaking through BCL-2 inhibition in CLL. Blood. 2020 03 05; 135(10):709-711.
journal title abbreviation: Blood
publication date: 2020-03-05T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1231563
type: Authorship
author rank in publication: 2
linked author: Davids, Matthew
linked information resource: Breaking through BCL-2 inhibition in CLL.

Authorship 1232388
type: Authorship
author rank in publication: 14
linked author: Davids, Matthew
linked information resource: Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma.

Authorship 1234612
type: Authorship
author rank in publication: 9
linked author: Davids, Matthew
linked information resource: Systematic literature review of the global burden of illness of mantle cell lymphoma.

Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma.
PubMed Identifier: 32126141
author list: Merryman RW, Edwin N, Redd R, Bsat J, Chase M, LaCasce A, Freedman A, Jacobson C, Fisher D, Ng S, Crombie J, Kim A, Odejide O, Davids MS, Brown JR, Jacene H, Cashen A, Bartlett NL, Mehta-Shah N, Ghobadi A, Kahl B, Joyce R, Armand P, Jacobsen E
published in: Blood advances
information resource reference: Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. Blood Adv. 2020 03 10; 4(5):858-867.
journal title abbreviation: Blood Adv
publication date: 2020-03-10T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Systematic literature review of the global burden of illness of mantle cell lymphoma.
PubMed Identifier: 32162977
author list: Monga N, Garside J, Quigley J, Hudson M, O'Donovan P, O'Rourke J, Tapprich C, Parisi L, Davids MS, Tam C
published in: Current medical research and opinion
information resource reference: Systematic literature review of the global burden of illness of mantle cell lymphoma. Curr Med Res Opin. 2020 05; 36(5):843-852.
journal title abbreviation: Curr Med Res Opin
publication date: 2020-03-31T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1237258
type: Authorship
author rank in publication: 3
linked author: Davids, Matthew
linked information resource: Small molecules, big impact: 20 years of targeted therapy in oncology.

Small molecules, big impact: 20 years of targeted therapy in oncology.
PubMed Identifier: 32222192
author list: Bedard PL, Hyman DM, Davids MS, Siu LL
published in: Lancet (London, England)
information resource reference: Small molecules, big impact: 20 years of targeted therapy in oncology. Lancet. 2020 03 28; 395(10229):1078-1088.
journal title abbreviation: Lancet
publication date: 2020-03-28T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1238637
type: Authorship
author rank in publication: 8
linked author: Davids, Matthew
linked information resource: The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites.

The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites.
PubMed Identifier: 32271900
author list: Mato A, Nabhan C, Lamanna N, Kay NE, Grinblatt DL, Flowers CR, Farber CM, Davids MS, Swern AS, Sullivan K, Flick ED, Gressett Ussery SM, Gharibo M, Kiselev P, Sharman JP
published in: Blood advances
information resource reference: The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites. Blood Adv. 2020 04 14; 4(7):1407-1418.
journal title abbreviation: Blood Adv
publication date: 2020-04-14T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors.
PubMed Identifier: 32282880
author list: Ryan CE, Cheng MP, Issa NC, Brown JR, Davids MS
published in: Blood advances
information resource reference: Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors. Blood Adv. 2020 04 14; 4(7):1458-1463.
journal title abbreviation: Blood Adv
publication date: 2020-04-14T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Acalabrutinib for the initial treatment of chronic lymphocytic leukaemia.
PubMed Identifier: 32305083
author list: Davids MS
published in: Lancet (London, England)
information resource reference: Acalabrutinib for the initial treatment of chronic lymphocytic leukaemia. Lancet. 2020 04 18; 395(10232):1234-1236.
journal title abbreviation: Lancet
publication date: 2020-04-18T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1240753
type: Authorship
author rank in publication: 5
linked author: Davids, Matthew
linked information resource: Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors.

Authorship 1240941
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: Acalabrutinib for the initial treatment of chronic lymphocytic leukaemia.

Authorship 1243585
type: Authorship
author rank in publication: 9
linked author: Davids, Matthew
linked information resource: Management of CLL patients early in the COVID-19 pandemic: An international survey of CLL experts.

Authorship 1242938
type: Authorship
author rank in publication: 4
linked author: Davids, Matthew
linked information resource: BTK Inhibitors in Cancer Patients with COVID-19: "The Winner Will be the One Who Controls That Chaos" (Napoleon Bonaparte).

BTK Inhibitors in Cancer Patients with COVID-19: "The Winner Will be the One Who Controls That Chaos" (Napoleon Bonaparte).
PubMed Identifier: 32345646
author list: Chong EA, Roeker LE, Shadman M, Davids MS, Schuster SJ, Mato AR
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: BTK Inhibitors in Cancer Patients with COVID-19: "The Winner Will be the One Who Controls That Chaos" (Napoleon Bonaparte). Clin Cancer Res. 2020 07 15; 26(14):3514-3516.
journal title abbreviation: Clin Cancer Res
publication date: 2020-04-28T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Management of CLL patients early in the COVID-19 pandemic: An international survey of CLL experts.
PubMed Identifier: 32356356
author list: Koffman B, Mato A, Byrd JC, Danilov A, Hedrick B, Ujjani C, Roeker L, Stephens DM, Davids MS, Pagel JM, Shadman M
published in: American journal of hematology
information resource reference: Management of CLL patients early in the COVID-19 pandemic: An international survey of CLL experts. Am J Hematol. 2020 08; 95(8):E199-E203.
journal title abbreviation: Am J Hematol
publication date: 2020-05-13T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1244631
type: Authorship
author rank in publication: 10
linked author: Davids, Matthew
linked information resource: Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States.

Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States.
PubMed Identifier: 32383129
author list: Cho SK, Manzoor BS, Sail KR, Parisé H, Ravelo A, Shapouri S, Kapustyan T, Sharmokh S, Virabhak S, Davids MS, Johnson S
published in: PharmacoEconomics
information resource reference: Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States. Pharmacoeconomics. 2020 09; 38(9):941-951.
journal title abbreviation: Pharmacoeconomics
publication date: 2020-09-01T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1253304
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation.

A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation.
PubMed Identifier: 32478814
author list: Davids MS, Kim HT, Costello C, Herrera AF, Locke FL, Maegawa RO, Savell A, Mazzeo M, Anderson A, Boardman AP, Weber A, Avigan D, Chen YB, Nikiforow S, Ho VT, Cutler C, Alyea EP, Bachireddy P, Wu CJ, Ritz J, Streicher H, Ball ED, Bashey A, Soiffer RJ, Armand P
published in: Blood
information resource reference: A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. Blood. 2020 06 11; 135(24):2182-2191.
journal title abbreviation: Blood
publication date: 2020-06-11T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Associate Professor of Medicine
is primary position: true
position in department: Medicine
position in division: Oncology
sort order: 1
type: Position
HR job title: Associate Professor of Medicine
position in organization: Dana-Farber Cancer Institute

Authorship 1268647
type: Authorship
author rank in publication: 12
linked author: Davids, Matthew
linked information resource: Outcomes of COVID-19 in patients with CLL: a multicenter international experience.

Outcomes of COVID-19 in patients with CLL: a multicenter international experience.
PubMed Identifier: 32688395
author list: Mato AR, Roeker LE, Lamanna N, Allan JN, Leslie L, Pagel JM, Patel K, Osterborg A, Wojenski D, Kamdar M, Huntington SF, Davids MS, Brown JR, Antic D, Jacobs R, Ahn IE, Pu J, Isaac KM, Barr PM, Ujjani CS, Geyer MB, Berman E, Zelenetz AD, Malakhov N, Furman RR, Koropsak M, Bailey N, Hanson L, Perini GF, Ma S, Ryan CE, Wiestner A, Portell CA, Shadman M, Chong EA, Brander DM, Sundaram S, Seddon AN, Seymour E, Patel M, Martinez-Calle N, Munir T, Walewska R, Broom A, Walter H, El-Sharkawi D, Parry H, Wilson MR, Patten PEM, Hernández-Rivas JÁ, Miras F, Fernández Escalada N, Ghione P, Nabhan C, Lebowitz S, Bhavsar E, López-Jiménez J, Naya D, Garcia-Marco JA, Skånland SS, Cordoba R, Eyre TA
published in: Blood
information resource reference: Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020 09 03; 136(10):1134-1143.
journal title abbreviation: Blood
publication date: 2020-09-03T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1275975
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients.

A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients.
PubMed Identifier: 32820271
author list: Davids MS, Fisher DC, Tyekucheva S, McDonough M, Hanna J, Lee B, Francoeur K, Montegaard J, Odejide O, Armand P, Arnason J, Brown JR
published in: Leukemia
information resource reference: A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients. Leukemia. 2021 04; 35(4):1064-1072.
journal title abbreviation: Leukemia
publication date: 2020-08-20T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1280488
type: Authorship
author rank in publication: 10
linked author: Davids, Matthew
linked information resource: Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents.

Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents.
PubMed Identifier: 32841336
author list: Roeker LE, Dreger P, Brown JR, Lahoud OB, Eyre TA, Brander DM, Skarbnik A, Coombs CC, Kim HT, Davids M, Manchini ST, George G, Shah N, Voorhees TJ, Orchard KH, Walter HS, Arumainathan AK, Sitlinger A, Park JH, Geyer MB, Zelenetz AD, Sauter CS, Giralt SA, Perales MA, Mato AR
published in: Blood advances
information resource reference: Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. Blood Adv. 2020 08 25; 4(16):3977-3989.
journal title abbreviation: Blood Adv
publication date: 2020-08-25T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1291589
type: Authorship
author rank in publication: 3
linked author: Davids, Matthew
linked information resource: Systematic Literature Review of Economic Evaluations, Costs/Resource Use, and Quality of Life in Patients with Mantle Cell Lymphoma.

Systematic Literature Review of Economic Evaluations, Costs/Resource Use, and Quality of Life in Patients with Mantle Cell Lymphoma.
PubMed Identifier: 32996067
author list: Monga N, Garside J, Davids MS, Tam C, Ward K, Fotheringham I, O'Donovan P, Parisi L, Tapprich C
published in: PharmacoEconomics - open
information resource reference: Systematic Literature Review of Economic Evaluations, Costs/Resource Use, and Quality of Life in Patients with Mantle Cell Lymphoma. Pharmacoecon Open. 2021 Jun; 5(2):175-186.
journal title abbreviation: Pharmacoecon Open
publication date: 2021-06-01T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1293872
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: Comparative Efficacy of Acalabrutinib in Frontline Treatment of Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis.

Comparative Efficacy of Acalabrutinib in Frontline Treatment of Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis.
PubMed Identifier: 33032842
author list: Davids MS, Waweru C, Le Nouveau P, Padhiar A, Singh G, Abhyankar S, Leblond V
published in: Clinical therapeutics
information resource reference: Comparative Efficacy of Acalabrutinib in Frontline Treatment of Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis. Clin Ther. 2020 10; 42(10):1955-1974.e15.
journal title abbreviation: Clin Ther
publication date: 2020-10-06T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1294919
type: Authorship
author rank in publication: 18
linked author: Davids, Matthew
linked information resource: Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration.

Authorship 1297982
type: Authorship
author rank in publication: 2
linked author: Davids, Matthew
linked information resource: Idelalisib in indolent NHL - has it finally found its niche?

Authorship 1295836
type: Authorship
author rank in publication: 10
linked author: Davids, Matthew
linked information resource: A deep molecular response of splenic marginal zone lymphoma to front-line checkpoint blockade.

A deep molecular response of splenic marginal zone lymphoma to front-line checkpoint blockade.
PubMed Identifier: 33054119
author list: Miller PG, Sperling AS, Gibson CJ, Pozdnyakova O, Wong WJ, Manos MP, Buchbinder EI, Hodi FS, Ebert BL, Davids MS
published in: Haematologica
information resource reference: A deep molecular response of splenic marginal zone lymphoma to front-line checkpoint blockade. Haematologica. 2021 02 01; 106(2):651-654.
journal title abbreviation: Haematologica
publication date: 2021-02-01T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration.
PubMed Identifier: 33054118
author list: Stephens DM, Boucher K, Kander E, Parikh SA, Parry EM, Shadman M, Pagel JM, Cooperrider J, Rhodes J, Mato A, Winter A, Hill B, Gaballa S, Danilov A, Phillips T, Brander DM, Smith SM, Davids M, Rogers K, Glenn MJ, Byrd JC
published in: Haematologica
information resource reference: Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration. Haematologica. 2021 11 01; 106(11):2845-2852.
journal title abbreviation: Haematologica
publication date: 2021-11-01T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Idelalisib in indolent NHL - has it finally found its niche?
PubMed Identifier: 33076732
author list: Sekar A, Davids MS
published in: Leukemia & lymphoma
information resource reference: Idelalisib in indolent NHL - has it finally found its niche? Leuk Lymphoma. 2021 05; 62(5):1029-1030.
journal title abbreviation: Leuk Lymphoma
publication date: 2020-10-19T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Serine-70 phosphorylated Bcl-2 prevents oxidative stress-induced DNA damage by modulating the mitochondrial redox metabolism.
PubMed Identifier: 33245769
author list: Chong SJF, Iskandar K, Lai JXH, Qu J, Raman D, Valentin R, Herbaux C, Collins M, Low ICC, Loh T, Davids M, Pervaiz S
published in: Nucleic acids research
information resource reference: Serine-70 phosphorylated Bcl-2 prevents oxidative stress-induced DNA damage by modulating the mitochondrial redox metabolism. Nucleic Acids Res. 2020 12 16; 48(22):12727-12745.
journal title abbreviation: Nucleic Acids Res
publication date: 2020-12-16T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1302386
type: Authorship
author rank in publication: 22
linked author: Davids, Matthew
linked information resource: miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors.

Authorship 1307285
type: Authorship
author rank in publication: 8
linked author: Davids, Matthew
linked information resource: A prospective study of minimal residual disease in patients with diffuse large B-cell lymphoma using an Ig-NGS assay.

Authorship 1303675
type: Authorship
author rank in publication: 11
linked author: Davids, Matthew
linked information resource: Serine-70 phosphorylated Bcl-2 prevents oxidative stress-induced DNA damage by modulating the mitochondrial redox metabolism.

miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors.
PubMed Identifier: 33171493
author list: Sharma S, Pavlasova GM, Seda V, Cerna KA, Vojackova E, Filip D, Ondrisova L, Sandova V, Kostalova L, Zeni PF, Borsky M, Oppelt J, Liskova K, Kren L, Janikova A, Pospisilova S, Fernandes SM, Shehata M, Rassenti LZ, Jaeger U, Doubek M, Davids MS, Brown JR, Mayer J, Kipps TJ, Mraz M
published in: Blood
information resource reference: miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors. Blood. 2021 05 06; 137(18):2481-2494.
journal title abbreviation: Blood
publication date: 2021-05-06T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

A prospective study of minimal residual disease in patients with diffuse large B-cell lymphoma using an Ig-NGS assay.
PubMed Identifier: 33236969
author list: Chase ML, Merryman R, Fisher DC, Jacobsen E, LaCasce A, Jacobson C, Freedman A, Davids MS, Brown JR, Jacob A, Armand P, Crombie J
published in: Leukemia & lymphoma
information resource reference: A prospective study of minimal residual disease in patients with diffuse large B-cell lymphoma using an Ig-NGS assay. Leuk Lymphoma. 2021 02; 62(2):478-481.
journal title abbreviation: Leuk Lymphoma
publication date: 2020-11-25T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1314514
type: Authorship
author rank in publication: 17
linked author: Davids, Matthew
linked information resource: Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses.

Authorship 1314553
type: Authorship
author rank in publication: 4
linked author: Davids, Matthew
linked information resource: Clinical efficacy and safety of first-line treatments in patients with mantle cell lymphoma: A systematic literature review.

Clinical efficacy and safety of first-line treatments in patients with mantle cell lymphoma: A systematic literature review.
PubMed Identifier: 33383209
author list: Monga N, Tam C, Garside J, Davids MS, Ward K, Quigley J, Parisi L, Tapprich C
published in: Critical reviews in oncology/hematology
information resource reference: Clinical efficacy and safety of first-line treatments in patients with mantle cell lymphoma: A systematic literature review. Crit Rev Oncol Hematol. 2021 Feb; 158:103212.
journal title abbreviation: Crit Rev Oncol Hematol
publication date: 2020-12-28T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses.
PubMed Identifier: 33373063
author list: Brown JR, Walker SR, Heppler LN, Tyekucheva S, Nelson EA, Klitgaard J, Nicolais M, Kroll Y, Xiang M, Yeh JE, Chaudhury M, Giaccone ZT, Fernandes SM, Jacobsen ED, Fisher DC, Freedman AS, Davids MS, Supko JG, Wu C, Frank DA
published in: American journal of hematology
information resource reference: Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses. Am J Hematol. 2021 04 01; 96(4):E95-E98.
journal title abbreviation: Am J Hematol
publication date: 2021-01-11T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia.
PubMed Identifier: 33598678
author list: Herbaux C, Kornauth C, Poulain S, Chong SJF, Collins MC, Valentin R, Hackett L, Tournilhac O, Lemonnier F, Dupuis J, Daniel A, Tomowiak C, Laribi K, Renaud L, Roos-Weil D, Rossi C, Van Den Neste E, Leyronnas C, Merabet F, Malfuson JV, Tiab M, Ysebaert L, Ng S, Morschhauser F, Staber PB, Davids MS
published in: Blood
information resource reference: BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia. Blood. 2021 06 24; 137(25):3495-3506.
journal title abbreviation: Blood
publication date: 2021-06-24T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1331013
type: Authorship
author rank in publication: 26
linked author: Davids, Matthew
linked information resource: BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia.

Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia.
PubMed Identifier: 33626863
author list: Kornauth C, Herbaux C, Boidol B, Guillemette C, Caron P, Mayerhöfer ME, Poulain S, Tournilhac O, Pemovska T, Chong SJF, Van der Kouwe E, Kazianka L, Hopfinger G, Heintel D, Jäger R, Raderer M, Jäger U, Simonitsch-Klupp I, Sperr WR, Kubicek S, Davids MS, Staber PB
published in: Haematologica
information resource reference: Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia. Haematologica. 2021 08 01; 106(8):2251-2256.
journal title abbreviation: Haematologica
publication date: 2021-08-01T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1334404
type: Authorship
author rank in publication: 21
linked author: Davids, Matthew
linked information resource: Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia.

Authorship 1337191
type: Authorship
author rank in publication: 31
linked author: Davids, Matthew
linked information resource: Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
PubMed Identifier: 33676628
author list: Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, Fakhri B, Eyre TA, Lamanna N, Patel MR, Alencar A, Lech-Maranda E, Wierda WG, Coombs CC, Gerson JN, Ghia P, Le Gouill S, Lewis DJ, Sundaram S, Cohen JB, Flinn IW, Tam CS, Barve MA, Kuss B, Taylor J, Abdel-Wahab O, Schuster SJ, Palomba ML, Lewis KL, Roeker LE, Davids MS, Tan XN, Fenske TS, Wallin J, Tsai DE, Ku NC, Zhu E, Chen J, Yin M, Nair B, Ebata K, Marella N, Brown JR, Wang M
published in: Lancet (London, England)
information resource reference: Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021 03 06; 397(10277):892-901.
journal title abbreviation: Lancet
publication date: 2021-03-06T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation.
PubMed Identifier: 33720354
author list: Penter L, Zhang Y, Savell A, Huang T, Cieri N, Thrash EM, Kim-Schulze S, Jhaveri A, Fu J, Ranasinghe S, Li S, Zhang W, Hathaway ES, Nazzaro M, Kim HT, Chen H, Thurin M, Rodig SJ, Severgnini M, Cibulskis C, Gabriel S, Livak KJ, Cutler C, Antin JH, Nikiforow S, Koreth J, Ho VT, Armand P, Ritz J, Streicher H, Neuberg D, Hodi FS, Gnjatic S, Soiffer RJ, Liu XS, Davids MS, Bachireddy P, Wu CJ
published in: Blood
information resource reference: Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. Blood. 2021 06 10; 137(23):3212-3217.
journal title abbreviation: Blood
publication date: 2021-06-10T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1339993
type: Authorship
author rank in publication: 36
linked author: Davids, Matthew
linked information resource: Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation.

Authorship 1349594
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: Highlights in chronic lymphocytic leukemia from the 62nd American Society of Hematology Annual Meeting and Exposition: commentary.

Highlights in chronic lymphocytic leukemia from the 62nd American Society of Hematology Annual Meeting and Exposition: commentary.
PubMed Identifier: 33843888
author list: Davids MS
published in: Clinical advances in hematology & oncology : H&O
information resource reference: Highlights in chronic lymphocytic leukemia from the 62nd American Society of Hematology Annual Meeting and Exposition: commentary. Clin Adv Hematol Oncol. 2021 Jan; 19 Suppl 4(1):21-23.
journal title abbreviation: Clin Adv Hematol Oncol
publication date: 2021-01-01T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1353010
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-naïve chronic lymphocytic leukemia.

Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-naïve chronic lymphocytic leukemia.
PubMed Identifier: 33955326
author list: Davids MS, Telford C, Abhyankar S, Waweru C, Ringshausen I
published in: Leukemia & lymphoma
information resource reference: Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-naïve chronic lymphocytic leukemia. Leuk Lymphoma. 2021 10; 62(10):2342-2351.
journal title abbreviation: Leuk Lymphoma
publication date: 2021-05-06T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1360341
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study.

Authorship 1361246
type: Authorship
author rank in publication: 3
linked author: Davids, Matthew
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/181779082

https://connects.catalyst.harvard.edu/Profiles/profile/181779082
PubMed Identifier: 34074652
author list: Terraf P, Sholl LM, Davids MS, Awad MM, Garcia EP, MacConaill LE, Dal Cin P, Kim A, Lindeman NI, Stachler M, Hwang DH, Dubuc AM
published in: Cold Spring Harbor molecular case studies
information resource reference: Twists and turns from "tumor in tumor" profiling: surveillance of chronic lymphocytic leukemia (CLL) leads to detection of a lung adenocarcinoma, whose genomic characterization alters the original hematologic diagnosis. Cold Spring Harb Mol Case Stud. 2021 08; 7(4).
journal title abbreviation: Cold Spring Harb Mol Case Stud
publication date: 2021-08-02T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Twists and turns from "tumor in tumor" profiling: surveillance of chronic lymphocytic leukemia (CLL) leads to detection of a lung adenocarcinoma, whose genomic characterization alters the original hematologic diagnosis.

Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study.
PubMed Identifier: 34083230
author list: Davids MS, Roberts AW, Kenkre VP, Wierda WG, Kumar A, Kipps TJ, Boyer M, Salem AH, Pesko JC, Arzt JA, Mantas M, Kim SY, Seymour JF
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study. Clin Cancer Res. 2021 09 01; 27(17):4690-4695.
journal title abbreviation: Clin Cancer Res
publication date: 2021-06-03T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1362350
type: Authorship
author rank in publication: 16
linked author: Davids, Matthew
linked information resource: Longitudinal Single-Cell Dynamics of Chromatin Accessibility and Mitochondrial Mutations in Chronic Lymphocytic Leukemia Mirror Disease History.

Longitudinal Single-Cell Dynamics of Chromatin Accessibility and Mitochondrial Mutations in Chronic Lymphocytic Leukemia Mirror Disease History.
PubMed Identifier: 34112698
author list: Penter L, Gohil SH, Lareau C, Ludwig LS, Parry EM, Huang T, Li S, Zhang W, Livitz D, Leshchiner I, Parida L, Getz G, Rassenti LZ, Kipps TJ, Brown JR, Davids MS, Neuberg DS, Livak KJ, Sankaran VG, Wu CJ
published in: Cancer discovery
information resource reference: Longitudinal Single-Cell Dynamics of Chromatin Accessibility and Mitochondrial Mutations in Chronic Lymphocytic Leukemia Mirror Disease History. Cancer Discov. 2021 12 01; 11(12):3048-3063.
journal title abbreviation: Cancer Discov
publication date: 2021-12-01T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

The redox-senescence axis and its therapeutic targeting.
PubMed Identifier: 34147844
author list: Ngoi NY, Liew AQ, Chong SJF, Davids MS, Clement MV, Pervaiz S
published in: Redox biology
information resource reference: The redox-senescence axis and its therapeutic targeting. Redox Biol. 2021 09; 45:102032.
journal title abbreviation: Redox Biol
publication date: 2021-06-05T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1371770
type: Authorship
author rank in publication: 4
linked author: Davids, Matthew
linked information resource: The redox-senescence axis and its therapeutic targeting.

Authorship 1370836
type: Authorship
author rank in publication: 12
linked author: Davids, Matthew
linked information resource: IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3Kd inhibitor idelalisib.

IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3Kd inhibitor idelalisib.
PubMed Identifier: 34196167
author list: Sandova V, Pavlasova GM, Seda V, Cerna KA, Sharma S, Palusova V, Brychtova Y, Pospisilova S, Fernandes SM, Panovska A, Doubek M, Davids MS, Brown JR, Mayer J, Mraz M
published in: Haematologica
information resource reference: IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3Kd inhibitor idelalisib. Haematologica. 2021 11 01; 106(11):2995-2999.
journal title abbreviation: Haematologica
publication date: 2021-11-01T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1378030
type: Authorship
author rank in publication: 6
linked author: Davids, Matthew
linked information resource: COVID-19 in patients with CLL: improved survival outcomes and update on management strategies.

COVID-19 in patients with CLL: improved survival outcomes and update on management strategies.
PubMed Identifier: 34297826
author list: Roeker LE, Eyre TA, Thompson MC, Lamanna N, Coltoff AR, Davids MS, Baker PO, Leslie L, Rogers KA, Allan JN, Cordoba R, Lopez-Garcia A, Antic D, Pagel JM, Martinez-Calle N, García-Marco JA, Hernández-Rivas JÁ, Miras F, Coombs CC, Österborg A, Hansson L, Seddon AN, López Jiménez J, Wilson MR, El-Sharkawi D, Wojenski D, Ma S, Munir T, Valenciano S, Seymour E, Barr PM, Pu J, Patten PEM, Perini GF, Huntington SF, Parry H, Sundaram S, Skarbnik A, Kamdar M, Jacobs R, Walter H, Walewska R, Broom A, Lebowitz S, Isaac KM, Portell CA, Ahn IE, Ujjani CS, Shadman M, Skånland SS, Chong EA, Mato AR
published in: Blood
information resource reference: COVID-19 in patients with CLL: improved survival outcomes and update on management strategies. Blood. 2021 11 04; 138(18):1768-1773.
journal title abbreviation: Blood
publication date: 2021-11-04T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1385009
type: Authorship
author rank in publication: 15
linked author: Davids, Matthew
linked information resource: Activity of mRNA COVID-19 vaccines in patients with lymphoid malignancies.

Activity of mRNA COVID-19 vaccines in patients with lymphoid malignancies.
PubMed Identifier: 34387646
author list: Crombie JL, Sherman AC, Cheng CA, Ryan CE, Zon R, Desjardins M, Baker P, McDonough M, Izaguirre N, Bausk B, Krauss J, Gilboa T, Senussi Y, Walt DR, Davids MS, Brown JR, Armand P, Baden LR, Issa N
published in: Blood advances
information resource reference: Activity of mRNA COVID-19 vaccines in patients with lymphoid malignancies. Blood Adv. 2021 08 24; 5(16):3062-3065.
journal title abbreviation: Blood Adv
publication date: 2021-08-24T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Ahn, Inhye
eCommons Login: ina323
first name: Inhye
last name: Ahn
full name: Inhye Ahn, M.D.
has faculty rank: Assistant Professor
Person ID: 200835
person in primary position: Assistant Professor of Medicine
type: Agent
type: Person
preferred title: Assistant Professor of Medicine

Authorship 1388710
type: Authorship
author rank in publication: 4
linked author: Davids, Matthew
linked information resource: Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation.

Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation.
PubMed Identifier: 34435483
author list: Kim HT, Baker PO, Parry E, Davids M, Alyea EP, Ho VT, Cutler C, Koreth J, Gooptu M, Romee R, Nikiforow S, Antin JH, Ritz J, Soiffer RJ, Wu CJ, Brown JR
published in: Haematologica
information resource reference: Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation. Haematologica. 2021 12 01; 106(12):3219-3222.
journal title abbreviation: Haematologica
publication date: 2021-12-01T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1394264
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study.

Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study.
PubMed Identifier: 34534514
author list: Davids MS, Lampson BL, Tyekucheva S, Wang Z, Lowney JC, Pazienza S, Montegaard J, Patterson V, Weinstock M, Crombie JL, Ng SY, Kim AI, Jacobson CA, LaCasce AS, Armand P, Arnason JE, Fisher DC, Brown JR
published in: The Lancet. Oncology
information resource reference: Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study. Lancet Oncol. 2021 10; 22(10):1391-1402.
journal title abbreviation: Lancet Oncol
publication date: 2021-09-14T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1396889
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: Integrated safety analysis of umbralisib, a dual PI3Kd/CK1e inhibitor, in relapsed/refractory lymphoid malignancies.

Integrated safety analysis of umbralisib, a dual PI3Kd/CK1e inhibitor, in relapsed/refractory lymphoid malignancies.
PubMed Identifier: 34547767
author list: Davids MS, O'Connor OA, Jurczak W, Samaniego F, Fenske TS, Zinzani PL, Patel MR, Ghosh N, Cheson BD, Derenzini E, Brander DM, Reeves JA, Knopinska-Posluszny W, Allan JN, Phillips T, Caimi PF, Lech-Maranda E, Burke JM, Agajanian R, Pettengell R, Leslie LA, Cheah CY, Fonseca G, Essell J, Chavez JC, Pagel JM, Sharman JP, Hsu Y, Miskin HP, Sportelli P, Weiss MS, Flinn IW
published in: Blood advances
information resource reference: Integrated safety analysis of umbralisib, a dual PI3Kd/CK1e inhibitor, in relapsed/refractory lymphoid malignancies. Blood Adv. 2021 12 14; 5(23):5332-5343.
journal title abbreviation: Blood Adv
publication date: 2021-12-14T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1405100
type: Authorship
author rank in publication: 11
linked author: Davids, Matthew
linked information resource: Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma.

Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma.
PubMed Identifier: 34670169
author list: Merryman RW, Redd R, Jeter E, Wong JL, McHugh K, Reynolds C, Nazzaro M, Varden A, Brown JR, Crombie JL, Davids MS, Fisher DC, Jacobsen E, Jacobson CA, Kim AI, LaCasce AS, Ng SY, Odejide OO, Parry EM, Dahi PB, Nieto Y, Joyce RM, Chen YB, Herrera AF, Armand P, Ritz J
published in: Transplantation and cellular therapy
information resource reference: Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma. Transplant Cell Ther. 2022 01; 28(1):32.e1-32.e10.
journal title abbreviation: Transplant Cell Ther
publication date: 2021-10-17T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1406636
type: Authorship
author rank in publication: 8
linked author: Davids, Matthew
linked information resource: Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States.

Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States.
PubMed Identifier: 34714110
author list: Chatterjee A, Shapouri S, Manzoor BS, Ravelo A, Sail K, Qendri V, van de Wetering G, Davids MS
published in: Journal of managed care & specialty pharmacy
information resource reference: Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States. J Manag Care Spec Pharm. 2021 Nov; 27(11):1532-1544.
journal title abbreviation: J Manag Care Spec Pharm
publication date: 2021-11-01T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1409816
type: Authorship
author rank in publication: 21
linked author: Davids, Matthew
linked information resource: Venetoclax in Previously Treated Waldenström Macroglobulinemia.

Authorship 1415041
type: Authorship
author rank in publication: 17
linked author: Davids, Matthew
linked information resource: A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia.

Authorship 1412712
type: Authorship
author rank in publication: 11
linked author: Davids, Matthew
linked information resource: Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy.

Authorship 1413570
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome.

Authorship 1410927
type: Authorship
author rank in publication: 2
linked author: Davids, Matthew
linked information resource: Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past Is Prologue" (Shakespeare).

A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia.
PubMed Identifier: 34743191
author list: Gadi D, Griffith A, Tyekucheva S, Wang Z, Rai V, Vartanov A, Thrash E, Fernandes SM, Lehmberg TZ, Lee B, Martindale SP, Machado JH, Odejide O, Armand P, Fisher DC, Arnason J, Davids MS, Lederer JA, Brown JR
published in: Leukemia
information resource reference: A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia. Leukemia. 2022 03; 36(3):723-732.
journal title abbreviation: Leukemia
publication date: 2021-11-06T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy.
PubMed Identifier: 34779028
author list: Popovic R, Dunbar F, Lu C, Robinson K, Quarless D, Warder SE, Mukherjee N, Pesko J, Souers AJ, Waring JF, Davids MS, Tausch E, Stilgenbauer S, Ross JA, Leverson JD, Kim SY, Chyla BJ
published in: American journal of hematology
information resource reference: Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy. Am J Hematol. 2022 02 01; 97(2):E47-E51.
journal title abbreviation: Am J Hematol
publication date: 2021-11-24T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past Is Prologue" (Shakespeare).
PubMed Identifier: 34789482
author list: Mato AR, Davids MS, Sharman J, Roeker LE, Kay N, Kater AP, Rogers K, Thompson MC, Rhodes J, Goy A, Skarbnik A, Schuster SJ, Tam CS, Eyre TA, O'Brien S, Nabhan C, Lamanna N, Sun C, Shadman M, Pagel JM, Ujjani C, Brander D, Coombs CC, Jain N, Cheah CY, Brown JR, Seymour JF, Woyach JA
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past Is Prologue" (Shakespeare). Clin Cancer Res. 2022 02 15; 28(4):603-608.
journal title abbreviation: Clin Cancer Res
publication date: 2022-02-15T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

Venetoclax in Previously Treated Waldenström Macroglobulinemia.
PubMed Identifier: 34793256
author list: Castillo JJ, Allan JN, Siddiqi T, Advani RH, Meid K, Leventoff C, White TP, Flynn CA, Sarosiek S, Branagan AR, Demos MG, Guerrera ML, Kofides A, Liu X, Munshi M, Tsakmaklis N, Xu L, Yang G, Patterson CJ, Hunter ZR, Davids MS, Furman RR, Treon SP
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Venetoclax in Previously Treated Waldenström Macroglobulinemia. J Clin Oncol. 2022 01 01; 40(1):63-71.
journal title abbreviation: J Clin Oncol
publication date: 2021-11-18T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome.
PubMed Identifier: 34788401
author list: Davids MS, Rogers KA, Tyekucheva S, Wang Z, Pazienza S, Renner SK, Montegaard J, Ihuoma U, Lehmberg TZ, Parry EM, Wu CJ, Jacobson CA, Fisher DC, Thompson PA, Brown JR
published in: Blood
information resource reference: Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome. Blood. 2022 02 03; 139(5):686-689.
journal title abbreviation: Blood
publication date: 2022-02-03T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1421024
type: Authorship
author rank in publication: 10
linked author: Davids, Matthew
linked information resource: Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies.

Authorship 1420994
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: A multicenter, retrospective study of accelerated venetoclax ramp-up in patients with relapsed/refractory chronic lymphocytic leukemia.

Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies.
PubMed Identifier: 34937320
author list: Allan JN, Pinilla-Ibarz J, Gladstone DE, Patel K, Sharman JP, Wierda WG, Choi MY, O'Brien SM, Shadman M, Davids MS, Pagel JM, Yimer HA, Ward R, Acton G, Taverna P, Combs DL, Fox JA, Furman RR, Brown JR
published in: Haematologica
information resource reference: Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies. Haematologica. 2022 04 01; 107(4):984-987.
journal title abbreviation: Haematologica
publication date: 2022-04-01T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

A multicenter, retrospective study of accelerated venetoclax ramp-up in patients with relapsed/refractory chronic lymphocytic leukemia.
PubMed Identifier: 34929063
author list: Davids MS, Shadman M, Parikh SA, Ujjani C, Crombie JL, Jiang D, Llamas C, Feng D, Lamanna N
published in: American journal of hematology
information resource reference: A multicenter, retrospective study of accelerated venetoclax ramp-up in patients with relapsed/refractory chronic lymphocytic leukemia. Am J Hematol. 2022 03 01; 97(3):E105-E109.
journal title abbreviation: Am J Hematol
publication date: 2022-01-07T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology
is primary position: true
position in department: Medicine
position in division: Oncology
sort order: 1
type: Position
HR job title: Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology
position in organization: Dana-Farber Cancer Institute

Assistant Professor of Medicine
is primary position: true
position in department: Medicine
position in division: Oncology
sort order: 1
type: Position
HR job title: Assistant Professor of Medicine
position in organization: Dana-Farber Cancer Institute

Authorship 1465659
type: Authorship
author rank in publication: 8
linked author: Davids, Matthew
linked information resource: Longitudinal health-related quality of life in first-line treated patients with chronic lymphocytic leukemia: Results from the Connect® CLL Registry.

Authorship 1465381
type: Authorship
author rank in publication: 4
linked author: Davids, Matthew
linked information resource: Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy.

Authorship 1463276
type: Authorship
author rank in publication: 4
linked author: Davids, Matthew
linked information resource: PI3K inhibitors in haematological malignancies.

Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy.
PubMed Identifier: 35845292
author list: Handunnetti S, Anderson MA, Roberts AW, Davids MS, Ma S, Boyer M, Arzt J, Masud AA, Popovic R, Jacobson A, Kim SY, Seymour JF
published in: EJHaem
information resource reference: Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy. EJHaem. 2021 May; 2(2):266-271.
journal title abbreviation: EJHaem
publication date: 2021-03-03T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

PI3K inhibitors in haematological malignancies.
PubMed Identifier: 35901825
author list: Brown JR, Danilov AV, LaCasce AS, Davids MS
published in: The Lancet. Oncology
information resource reference: PI3K inhibitors in haematological malignancies. Lancet Oncol. 2022 08; 23(8):e364.
journal title abbreviation: Lancet Oncol
publication date: 2022-08-01T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

Longitudinal health-related quality of life in first-line treated patients with chronic lymphocytic leukemia: Results from the Connect® CLL Registry.
PubMed Identifier: 35847738
author list: Sharman JP, Cocks K, Nabhan C, Lamanna N, Kay NE, Grinblatt DL, Flowers CR, Davids MS, Kiselev P, Swern AS, Sullivan K, Gharibo MM, Flick ED, Trigg A, Mato A
published in: EJHaem
information resource reference: Longitudinal health-related quality of life in first-line treated patients with chronic lymphocytic leukemia: Results from the Connect® CLL Registry. EJHaem. 2020 Jul; 1(1):188-198.
journal title abbreviation: EJHaem
publication date: 2020-07-26T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Associate Professor of Medicine
is primary position: true
position in department: Medicine
position in division: Oncology
sort order: 1
type: Position
HR job title: Associate Professor of Medicine
position in organization: Dana-Farber Cancer Institute

Authorship 1482176
type: Authorship
author rank in publication: 2
linked author: Davids, Matthew
linked information resource: MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.

Authorship 1488808
type: Authorship
author rank in publication: 18
linked author: Davids, Matthew
linked information resource: Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance.

Authorship 1502991
type: Authorship
author rank in publication: 25
linked author: Davids, Matthew
linked information resource: Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings.

Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings.
PubMed Identifier: 36332187
author list: Garcia JS, Flamand Y, Penter L, Keng M, Tomlinson BK, Mendez LM, Koller P, Cullen N, Arihara Y, Pfaff K, Wolff JO, Brunner AM, Galinsky I, Bashey A, Antin JH, Cutler C, Ho V, Jonas BA, Luskin MR, Wadleigh M, Winer ES, Savell A, Leonard R, Robertson T, Davids MS, Streicher H, Rodig SJ, Ritz J, Wu CJ, DeAngelo DJ, Neuberg D, Stone RM, Soiffer RJ
published in: Blood
information resource reference: Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings. Blood. 2023 04 13; 141(15):1884-1888.
journal title abbreviation: Blood
publication date: 2023-04-13T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
PubMed Identifier: 36102212
author list: Ryan CE, Davids MS, Hermann R, Shahkarami M, Biondo J, Abhyankar S, Alhasani H, Sharman JP, Mato AR, Roeker LE
published in: Future oncology (London, England)
information resource reference: MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. Future Oncol. 2022 Oct; 18(33):3689-3699.
journal title abbreviation: Future Oncol
publication date: 2022-09-14T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance.
PubMed Identifier: 36287227
author list: Naeem A, Utro F, Wang Q, Cha J, Vihinen M, Martindale S, Zhou Y, Ren Y, Tyekucheva S, Kim AS, Fernandes SM, Saksena G, Rhrissorrakrai K, Levovitz C, Danysh BP, Slowik K, Jacobs RA, Davids MS, Lederer JA, Zain R, Smith CIE, Leshchiner I, Parida L, Getz G, Brown JR
published in: Blood advances
information resource reference: Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance. Blood Adv. 2023 05 09; 7(9):1929-1943.
journal title abbreviation: Blood Adv
publication date: 2023-05-09T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1503824
type: Authorship
author rank in publication: 9
linked author: Davids, Matthew
linked information resource: Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation.

Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation.
PubMed Identifier: 36399518
author list: Merryman RW, Redd RA, Taranto E, Ahmed G, Jeter E, McHugh KM, Brown JR, Crombie JL, Davids MS, Fisher DC, Freedman AS, Jacobsen E, Jacobson CA, Kim AI, LaCasce AS, Ng SY, Odejide OO, Parry EM, Jacene H, Park H, Dahi PB, Nieto Y, Joyce RM, Chen YB, Shipp MA, Herrera AF, Armand P
published in: Blood advances
information resource reference: Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. Blood Adv. 2023 09 12; 7(17):4748-4759.
journal title abbreviation: Blood Adv
publication date: 2023-09-12T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1509145
type: Authorship
author rank in publication: 34
linked author: Davids, Matthew
linked information resource: In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities.

In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities.
PubMed Identifier: 36468984
author list: Ten Hacken E, Sewastianik T, Yin S, Hoffmann GB, Gruber M, Clement K, Penter L, Redd RA, Ruthen N, Hergalant S, Sholokhova A, Fell G, Parry EM, Broséus J, Guieze R, Lucas F, Hernández-Sánchez M, Baranowski K, Southard J, Joyal H, Billington L, Regis FFD, Witten E, Uduman M, Knisbacher BA, Li S, Lyu H, Vaisitti T, Deaglio S, Inghirami G, Feugier P, Stilgenbauer S, Tausch E, Davids MS, Getz G, Livak KJ, Bozic I, Neuberg DS, Carrasco RD, Wu CJ
published in: Blood cancer discovery
information resource reference: In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities. Blood Cancer Discov. 2023 03 01; 4(2):150-169.
journal title abbreviation: Blood Cancer Discov
publication date: 2023-03-01T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1513446
type: Authorship
author rank in publication: 15
linked author: Davids, Matthew
linked information resource: Diminished humoral and cellular responses to SARS-CoV-2 vaccines in patients with chronic lymphocytic leukemia.

Diminished humoral and cellular responses to SARS-CoV-2 vaccines in patients with chronic lymphocytic leukemia.
PubMed Identifier: 36516082
author list: Ujjani C, Gooley TA, Spurgeon SE, Stephens DM, Lai C, Broome CM, O'Brien S, Zhu H, Laing KJ, Winter AM, Pongas G, Greninger AL, Koelle DM, Siddiqi T, Davids MS, Rogers KA, Danilov AV, Sperling A, Tu B, Sorensen T, Launchbury K, Burrow CJ, Quezada G, Hill JA, Shadman M, Thompson PA
published in: Blood advances
information resource reference: Diminished humoral and cellular responses to SARS-CoV-2 vaccines in patients with chronic lymphocytic leukemia. Blood Adv. 2023 09 12; 7(17):4728-4737.
journal title abbreviation: Blood Adv
publication date: 2023-09-12T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1515594
type: Authorship
author rank in publication: 49
linked author: Davids, Matthew
linked information resource: Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome.

Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome.
PubMed Identifier: 36624313
author list: Parry EM, Leshchiner I, Guièze R, Johnson C, Tausch E, Parikh SA, Lemvigh C, Broséus J, Hergalant S, Messer C, Utro F, Levovitz C, Rhrissorrakrai K, Li L, Rosebrock D, Yin S, Deng S, Slowik K, Jacobs R, Huang T, Li S, Fell G, Redd R, Lin Z, Knisbacher BA, Livitz D, Schneider C, Ruthen N, Elagina L, Taylor-Weiner A, Persaud B, Martinez A, Fernandes SM, Purroy N, Anandappa AJ, Ma J, Hess J, Rassenti LZ, Kipps TJ, Jain N, Wierda W, Cymbalista F, Feugier P, Kay NE, Livak KJ, Danysh BP, Stewart C, Neuberg D, Davids MS, Brown JR, Parida L, Stilgenbauer S, Getz G, Wu CJ
published in: Nature medicine
information resource reference: Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome. Nat Med. 2023 01; 29(1):158-169.
journal title abbreviation: Nat Med
publication date: 2023-01-09T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1518927
type: Authorship
author rank in publication: 30
linked author: Davids, Matthew
linked information resource: Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease.

Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease.
PubMed Identifier: 36706355
author list: Penter L, Liu Y, Wolff JO, Yang L, Taing L, Jhaveri A, Southard J, Patel M, Cullen NM, Pfaff KL, Cieri N, Oliveira G, Kim-Schulze S, Ranasinghe S, Leonard R, Robertson T, Morgan EA, Chen HX, Song MH, Thurin M, Li S, Rodig SJ, Cibulskis C, Gabriel S, Bachireddy P, Ritz J, Streicher H, Neuberg DS, Hodi FS, Davids MS, Gnjatic S, Livak KJ, Altreuter J, Michor F, Soiffer RJ, Garcia JS, Wu CJ
published in: Blood
information resource reference: Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease. Blood. 2023 04 13; 141(15):1817-1830.
journal title abbreviation: Blood
publication date: 2023-04-13T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1521537
type: Authorship
author rank in publication: 18
linked author: Davids, Matthew
linked information resource: A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia.

Authorship 1521396
type: Authorship
author rank in publication: 15
linked author: Davids, Matthew
linked information resource: Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma.

Authorship 1520882
type: Authorship
author rank in publication: 12
linked author: Davids, Matthew
linked information resource: Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kd inhibitors.

Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kd inhibitors.
PubMed Identifier: 36732326
author list: Gadi D, Martindale SP, Chiu PY, Khalsa J, Chen PH, Fernandes SM, Wang Z, Tyekucheva S, Machado JH, Fisher DC, Armand P, Davids MS, Rodig S, Sherry B, Brown JR
published in: Blood cancer journal
information resource reference: Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kd inhibitors. Blood Cancer J. 2023 02 02; 13(1):22.
journal title abbreviation: Blood Cancer J
publication date: 2023-02-02T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia.
PubMed Identifier: 36717653
author list: Ryan CE, Brander DM, Barr PM, Tyekucheva S, Hackett LR, Collins MC, Fernandes SM, Ren Y, Zhou Y, McDonough MM, Walker HA, McEwan MR, Abramson JS, Jacobsen ED, LaCasce AS, Fisher DC, Brown JR, Davids MS
published in: Leukemia
information resource reference: A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia. Leukemia. 2023 04; 37(4):835-842.
journal title abbreviation: Leukemia
publication date: 2023-01-30T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma.
PubMed Identifier: 36713355
author list: Merryman RW, Michaud L, Redd R, Mondello P, Park H, Spilberg G, Robertson M, Taranto E, Ahmed G, Chase M, Jeter E, Ahn IE, Brown JR, Crombie J, Davids MS, Fisher DC, Jacobsen E, Jacobson CA, Kim AI, LaCasce AS, Ng SY, Odejide OO, Parry EM, Salles G, Zelenetz AD, Armand P, Schöder H, Jacene H
published in: HemaSphere
information resource reference: Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma. Hemasphere. 2023 Feb; 7(2):e826.
journal title abbreviation: Hemasphere
publication date: 2023-01-24T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Hypomethylating agent decitabine sensitizes diffuse large B-cell lymphoma to venetoclax.
PubMed Identifier: 37534528
author list: Zhu F, Crombie JL, Ni W, Hoang NM, Garg S, Hackett L, Chong SJF, Collins MC, Rui L, Griffin J, Davids MS
published in: Haematologica
information resource reference: Hypomethylating agent decitabine sensitizes diffuse large B-cell lymphoma to venetoclax. Haematologica. 2024 01 01; 109(1):186-199.
journal title abbreviation: Haematologica
publication date: 2024-01-01T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1558596
type: Authorship
author rank in publication: 2
linked author: Davids, Matthew
linked information resource: Practical Management of Richter Transformation in 2023 and Beyond.

Authorship 1559332
type: Authorship
author rank in publication: 23
linked author: Davids, Matthew
linked information resource: Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samples.

Authorship 1564228
type: Authorship
author rank in publication: 22
linked author: Davids, Matthew
linked information resource: Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study.

Authorship 1563728
type: Authorship
author rank in publication: 11
linked author: Davids, Matthew
linked information resource: Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial.

Authorship 1559045
type: Authorship
author rank in publication: 20
linked author: Davids, Matthew
linked information resource: Targeted engagement of ß-catenin-Ikaros complexes in refractory B-cell malignancies.

Authorship 1568803
type: Authorship
author rank in publication: 5
linked author: Davids, Matthew
linked information resource: Targeting conditioned media dependencies and FLT-3 in chronic lymphocytic leukemia.

Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study.
PubMed Identifier: 37076367
author list: Shadman M, Manzoor BS, Sail K, Tuncer HH, Allan JN, Ujjani C, Emechebe N, Kamalakar R, Coombs CC, Leslie L, Barr PM, Brown JR, Eyre TA, Rampotas A, Schuh A, Lamanna N, Skarbnik A, Roeker LE, Bannerji R, Eichhorst B, Fleury I, Davids MS, Alhasani H, Jiang D, Hill BT, Schuster SJ, Brander DM, Pivneva I, Burne R, Guerin A, Mato AR
published in: Clinical lymphoma, myeloma & leukemia
information resource reference: Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study. Clin Lymphoma Myeloma Leuk. 2023 07; 23(7):515-526.
journal title abbreviation: Clin Lymphoma Myeloma Leuk
publication date: 2023-03-24T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Targeting conditioned media dependencies and FLT-3 in chronic lymphocytic leukemia.
PubMed Identifier: 37428863
author list: Parvin S, Aryal A, Yin S, Fell GG, Davids MS, Wu CJ, Letai A
published in: Blood advances
information resource reference: Targeting conditioned media dependencies and FLT-3 in chronic lymphocytic leukemia. Blood Adv. 2023 10 10; 7(19):5877-5889.
journal title abbreviation: Blood Adv
publication date: 2023-10-10T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Practical Management of Richter Transformation in 2023 and Beyond.
PubMed Identifier: 37141545
author list: Ryan CE, Davids MS
published in: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
information resource reference: Practical Management of Richter Transformation in 2023 and Beyond. Am Soc Clin Oncol Educ Book. 2023 Jan; 43:e390804.
journal title abbreviation: Am Soc Clin Oncol Educ Book
publication date: 2023-01-01T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Targeted engagement of ß-catenin-Ikaros complexes in refractory B-cell malignancies.
PubMed Identifier: 36993619
author list: Cosgun KN, Jumaa H, Robinson ME, Kistner KM, Xu L, Xiao G, Chan LN, Lee J, Kume K, Leveille E, Fonseca-Arce D, Khanduja D, Ng HL, Feldhahn N, Song J, Chan WC, Chen J, Taketo MM, Kothari S, Davids MS, Schjerven H, Jellusova J, Müschen M
published in: bioRxiv : the preprint server for biology
information resource reference: Targeted engagement of ß-catenin-Ikaros complexes in refractory B-cell malignancies. bioRxiv. 2023 Mar 15.
journal title abbreviation: bioRxiv
publication date: 2023-03-15T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samples.
PubMed Identifier: 37146250
author list: Khalsa JK, Cha J, Utro F, Naeem A, Murali I, Kuang Y, Vasquez K, Li L, Tyekucheva S, Fernandes SM, Veronese L, Guieze R, Sasi BK, Wang Z, Machado JH, Bai H, Alasfour M, Rhrissorrakrai K, Levovitz C, Danysh BP, Slowik K, Jacobs RA, Davids MS, Paweletz CP, Leshchiner I, Parida L, Getz G, Brown JR
published in: Blood
information resource reference: Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samples. Blood. 2023 08 03; 142(5):421-433.
journal title abbreviation: Blood
publication date: 2023-08-03T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial.
PubMed Identifier: 37074726
author list: Ailawadhi S, Chen Z, Huang B, Paulus A, Collins MC, Fu LT, Li M, Ahmad M, Men L, Wang H, Davids MS, Liang E, Mekala DJ, He Z, Lasica M, Yannakou CK, Parrondo R, Glass L, Yang D, Chanan-Khan A, Zhai Y
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial. Clin Cancer Res. 2023 07 05; 29(13):2385-2393.
journal title abbreviation: Clin Cancer Res
publication date: 2023-07-05T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies.
PubMed Identifier: 37751299
author list: Chong SJF, Zhu F, Dashevsky O, Mizuno R, Lai JX, Hackett L, Ryan CE, Collins MC, Iorgulescu JB, Guièze R, Penailillo J, Carrasco R, Hwang YC, Muñoz DP, Bouhaddou M, Lim YC, Wu CJ, Allan JN, Furman RR, Goh BC, Pervaiz S, Coppé JP, Mitsiades CS, Davids MS
published in: The Journal of clinical investigation
information resource reference: Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies. J Clin Invest. 2023 11 15; 133(22).
journal title abbreviation: J Clin Invest
publication date: 2023-11-15T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Systematic characterization of therapeutic vulnerabilities in Multiple Myeloma with Amp1q reveals increased sensitivity to the combination of MCL1 and PI3K inhibitors.
PubMed Identifier: 37577538
author list: Sklavenitis-Pistofidis R, Lightbody ED, Reidy M, Tsuji J, Aranha MP, Heilpern-Mallory D, Huynh D, Chong SJF, Hackett L, Haradhvala NJ, Wu T, Su NK, Berrios B, Alberge JB, Dutta A, Davids MS, Papaioannou M, Getz G, Ghobrial IM, Manier S
published in: bioRxiv : the preprint server for biology
information resource reference: Systematic characterization of therapeutic vulnerabilities in Multiple Myeloma with Amp1q reveals increased sensitivity to the combination of MCL1 and PI3K inhibitors. bioRxiv. 2023 Aug 03.
journal title abbreviation: bioRxiv
publication date: 2023-08-03T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1583084
type: Authorship
author rank in publication: 24
linked author: Davids, Matthew
linked information resource: Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies.

Authorship 1584715
type: Authorship
author rank in publication: 16
linked author: Davids, Matthew
linked information resource: Systematic characterization of therapeutic vulnerabilities in Multiple Myeloma with Amp1q reveals increased sensitivity to the combination of MCL1 and PI3K inhibitors.

Authorship 1581949
type: Authorship
author rank in publication: 22
linked author: Davids, Matthew
linked information resource: PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer.

Authorship 1583941
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: Management of Richter transformation.

Authorship 1592600
type: Authorship
author rank in publication: 11
linked author: Davids, Matthew
linked information resource: Hypomethylating agent decitabine sensitizes diffuse large B-cell lymphoma to venetoclax.

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer.
PubMed Identifier: 37596643
author list: Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH, Eng H, Nair MG, Makvandi P, Geoerger B, Kulke MH, Baird RD, Prabhu JS, Carbone D, Pecoraro C, Teh DBL, Sethi G, Cavalieri V, Lin KH, Javidi-Sharifi NR, Toska E, Davids MS, Brown JR, Diana P, Stebbing J, Fruman DA, Kumar AP
published in: Molecular cancer
information resource reference: PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023 08 18; 22(1):138.
journal title abbreviation: Mol Cancer
publication date: 2023-08-18T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Management of Richter transformation.
PubMed Identifier: 37530621
author list: Davids MS
published in: Clinical advances in hematology & oncology : H&O
information resource reference: Management of Richter transformation. Clin Adv Hematol Oncol. 2023 08; 21(8):449-451.
journal title abbreviation: Clin Adv Hematol Oncol
publication date: 2023-08-01T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Research Fellow in Medicine
is primary position: true
position in department: Medicine
position in division: Oncology
sort order: 1
type: Position
HR job title: Research Fellow in Medicine
position in organization: Dana-Farber Cancer Institute

Authorship 1600778
type: Authorship
author rank in publication: 7
linked author: Davids, Matthew
linked information resource: A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma.

A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma.
PubMed Identifier: 37851072
author list: Merryman RW, Redd RA, Freedman AS, Ahn IE, Brown JR, Crombie JL, Davids MS, Fisher DC, Jacobsen ED, Kim AI, LaCasce AS, Ng S, Odejide OO, Parry EM, Isufi I, Kline J, Cohen JB, Mehta-Shah N, Bartlett NL, Mei M, Kuntz TM, Wolff J, Rodig SJ, Armand P, Jacobson CA
published in: Annals of hematology
information resource reference: A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma. Ann Hematol. 2024 Jan; 103(1):185-198.
journal title abbreviation: Ann Hematol
publication date: 2023-10-18T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1610555
type: Authorship
author rank in publication: 10
linked author: Davids, Matthew
linked information resource: First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors.

Authorship 1609382
type: Authorship
author rank in publication: 2
linked author: Davids, Matthew
linked information resource: Overcoming Resistance in Chronic Lymphocytic Leukemia-Maybe Less Is More?

Authorship 1611336
type: Authorship
author rank in publication: 19
linked author: Davids, Matthew
linked information resource: PI3Kd activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine.

Authorship 1610751
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: Functional cure reported in CLL.

Authorship 1608475
type: Authorship
author rank in publication: 8
linked author: Davids, Matthew
linked information resource: Pirtobrutinib versus venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: a matching-adjusted indirect comparison.

First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors.
PubMed Identifier: 37971712
author list: Lakhani NJ, Rasco D, Wang H, Men L, Liang E, Fu T, Collins MC, Min P, Yin Y, Davids MS, Yang D, Zhai Y
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors. Clin Cancer Res. 2024 02 01; 30(3):506-521.
journal title abbreviation: Clin Cancer Res
publication date: 2024-02-01T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Pirtobrutinib versus venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: a matching-adjusted indirect comparison.
PubMed Identifier: 38031799
author list: Al-Sawaf O, Jen MH, Hess LM, Zhang J, Goebel B, Pagel JM, Abhyankar S, Davids MS, Eyre TA
published in: Haematologica
information resource reference: Pirtobrutinib versus venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: a matching-adjusted indirect comparison. Haematologica. 2024 06 01; 109(6):1866-1873.
journal title abbreviation: Haematologica
publication date: 2024-06-01T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Overcoming Resistance in Chronic Lymphocytic Leukemia-Maybe Less Is More?
PubMed Identifier: 38055246
author list: Al-Sawaf O, Davids MS
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Overcoming Resistance in Chronic Lymphocytic Leukemia-Maybe Less Is More? Clin Cancer Res. 2024 02 01; 30(3):471-473.
journal title abbreviation: Clin Cancer Res
publication date: 2024-02-01T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

PI3Kd activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine.
PubMed Identifier: 38014209
author list: Arribas AJ, Gaudio E, Napoli S, Yvon Herbaux CJ, Tarantelli C, Bordone RP, Cascione L, Munz N, Aresu L, Sgrignani J, Rinaldi A, Kwee I, Rossi D, Cavalli A, Zucca E, Stussi G, Stathis A, Sloss C, Davids MS, Bertoni F
published in: bioRxiv : the preprint server for biology
information resource reference: PI3Kd activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine. bioRxiv. 2023 Nov 16.
journal title abbreviation: bioRxiv
publication date: 2023-11-16T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Functional cure reported in CLL.
PubMed Identifier: 37995104
author list: Davids MS
published in: Blood
information resource reference: Functional cure reported in CLL. Blood. 2023 11 23; 142(21):1761-1763.
journal title abbreviation: Blood
publication date: 2023-11-23T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1617848
type: Authorship
author rank in publication: 23
linked author: Davids, Matthew
linked information resource: Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL.

Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL.
PubMed Identifier: 38163317
author list: Ahn IE, Brander DM, Ren Y, Zhou Y, Tyekucheva S, Walker HA, Black R, Montegaard J, Alencar A, Shune L, Omaira M, Jacobson CA, Armand P, Ng SY, Crombie J, Fisher DC, LaCasce AS, Arnason J, Hochberg EP, Takvorian RW, Abramson JS, Brown JR, Davids MS
published in: Blood advances
information resource reference: Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL. Blood Adv. 2024 02 27; 8(4):832-841.
journal title abbreviation: Blood Adv
publication date: 2024-02-27T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1619771
type: Authorship
author rank in publication: 15
linked author: Davids, Matthew
linked information resource: Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study.

Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study.
PubMed Identifier: 38190628
author list: Herling M, Dearden C, Zaja F, El-Sharkawi D, Ding W, Bellido M, Khot A, Tick L, Jacobsen E, Eyre TA, Roos-Weil D, Kadia T, Lucchini E, Pflug N, Davids MS, Pena G, Mukherjee N, Badawi M, Vizkelety T, Staber PB
published in: Blood advances
information resource reference: Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study. Blood Adv. 2024 02 27; 8(4):842-845.
journal title abbreviation: Blood Adv
publication date: 2024-02-27T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1626070
type: Authorship
author rank in publication: 4
linked author: Davids, Matthew
linked information resource: Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia.

Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia.
PubMed Identifier: 38290108
author list: Stilgenbauer S, Tausch E, Roberts AW, Davids MS, Eichhorst B, Hallek M, Hillmen P, Schneider C, Schetelig J, Böttcher S, Kater AP, Jiang Y, Boyer M, Popovic R, Ghanim MT, Moran M, Sinai WJ, Wang X, Mukherjee N, Chyla B, Wierda WG, Seymour JF
published in: Blood advances
information resource reference: Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia. Blood Adv. 2024 04 23; 8(8):1992-2004.
journal title abbreviation: Blood Adv
publication date: 2024-04-23T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1627118
type: Authorship
author rank in publication: 7
linked author: Davids, Matthew
linked information resource: Mutations Detected in Real World Clinical Sequencing during BTK Inhibitor Treatment in CLL.

Mutations Detected in Real World Clinical Sequencing during BTK Inhibitor Treatment in CLL.
PubMed Identifier: 38313250
author list: Brown J, Mashima K, Fernandes S, Naeem A, Shupe S, Fardoun R, Davids M
published in: Research square
information resource reference: Mutations Detected in Real World Clinical Sequencing during BTK Inhibitor Treatment in CLL. Res Sq. 2024 Jan 16.
journal title abbreviation: Res Sq
publication date: 2024-01-16T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1638960
type: Authorship
author rank in publication: 8
linked author: Davids, Matthew
linked information resource: Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study.

Authorship 1636895
type: Authorship
author rank in publication: 6
linked author: Davids, Matthew
linked information resource: A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia.

Authorship 1636959
type: Authorship
author rank in publication: 2
linked author: Davids, Matthew
linked information resource: Therapeutic targeting of apoptosis in chronic lymphocytic leukemia.

Therapeutic targeting of apoptosis in chronic lymphocytic leukemia.
PubMed Identifier: 38538512
author list: Ahn IE, Davids MS
published in: Seminars in hematology
information resource reference: Therapeutic targeting of apoptosis in chronic lymphocytic leukemia. Semin Hematol. 2024 04; 61(2):109-118.
journal title abbreviation: Semin Hematol
publication date: 2024-02-07T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study.
PubMed Identifier: 38552193
author list: Kittai AS, Bond D, Huang Y, Bhat SA, Blyth E, Byrd JC, Chavez JC, Davids MS, Dela Cruz JP, Dowling MR, Duffy C, Ho C, Jacobson C, Jaglowski S, Jain N, Lin KH, Miller C, McCarthy C, Omer Z, Parry E, Rai M, Rogers KA, Saha A, Schachter L, Scott H, Senapati J, Shadman M, Siddiqi T, Stephens DM, Vanguru V, Wierda W, Woyach JA, Thompson PA
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study. J Clin Oncol. 2024 Jun 10; 42(17):2071-2079.
journal title abbreviation: J Clin Oncol
publication date: 2024-03-29T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia.
PubMed Identifier: 38537065
author list: Hampel PJ, Swaminathan M, Rogers KA, Parry EM, Burger JA, Davids MS, Ding W, Ferrajoli A, Hyak JM, Jain N, Kenderian SS, Wang Y, Wierda WG, Woyach JA, Parikh SA, Thompson PA
published in: Blood advances
information resource reference: A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia. Blood Adv. 2024 05 28; 8(10):2342-2350.
journal title abbreviation: Blood Adv
publication date: 2024-05-28T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1641315
type: Authorship
author rank in publication: 11
linked author: Davids, Matthew
linked information resource: An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL.

An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL.
PubMed Identifier: 38598745
author list: Kittai AS, Allan JN, James D, Bridge H, Miranda M, Yong ASM, Fam F, Roos J, Shetty V, Skarbnik A, Davids MS
published in: Blood advances
information resource reference: An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL. Blood Adv. 2024 06 11; 8(11):2861-2869.
journal title abbreviation: Blood Adv
publication date: 2024-06-11T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Optimizing novel agent combination therapy for previously untreated, high risk chronic lymphocytic leukemia
end date: 2027-06-30
principal investigator name: DAVIDS, MATTHEW S
start date: 2022-09-15
type: Grant
sponsor award id: R01CA266298

Principal Investigator
type: Researcher Role
researcher role of: Davids, Matthew
contributes to: Optimizing novel agent combination therapy for previously untreated, high risk chronic lymphocytic leukemia

Authorship 1651742
type: Authorship
author rank in publication: 2
linked author: Davids, Matthew
linked information resource: Burden of Infection in Patients With and Without Secondary Immunodeficiency Disease Following Diagnosis of a Mature B Cell Malignancy.

Authorship 1646740
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trials.

Authorship 1650717
type: Authorship
author rank in publication: 3
linked author: Davids, Matthew
linked information resource: The phase III DUO trial of PI3K inhibitor duvelisib versus ofatumumab in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final analysis including overall survival.

The phase III DUO trial of PI3K inhibitor duvelisib versus ofatumumab in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final analysis including overall survival.
PubMed Identifier: 38813715
author list: Danilov AV, Flinn IW, Davids MS, Gregory B, Bentur O, Sidransky D, Brown JR
published in: Haematologica
information resource reference: The phase III DUO trial of PI3K inhibitor duvelisib versus ofatumumab in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final analysis including overall survival. Haematologica. 2024 Oct 01; 109(10):3379-3382.
journal title abbreviation: Haematologica
publication date: 2024-10-01T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Burden of Infection in Patients With and Without Secondary Immunodeficiency Disease Following Diagnosis of a Mature B Cell Malignancy.
PubMed Identifier: 38734499
author list: Richter J, Davids MS, Anderson-Smits C, Kamieniak M, Ren K, Hull M, Multani JK, Shah D, Siffel C
published in: Clinical lymphoma, myeloma & leukemia
information resource reference: Burden of Infection in Patients With and Without Secondary Immunodeficiency Disease Following Diagnosis of a Mature B Cell Malignancy. Clin Lymphoma Myeloma Leuk. 2024 Aug; 24(8):553-563.
journal title abbreviation: Clin Lymphoma Myeloma Leuk
publication date: 2024-04-10T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trials.
PubMed Identifier: 38640349
author list: Davids MS, Sharman JP, Ghia P, Woyach JA, Eyre TA, Jurczak W, Siddiqi T, Miranda P, Shahkarami M, Butturini A, Emeribe U, Byrd JC
published in: Blood advances
information resource reference: Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trials. Blood Adv. 2024 07 09; 8(13):3345-3359.
journal title abbreviation: Blood Adv
publication date: 2024-07-09T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1664169
type: Authorship
author rank in publication: 3
linked author: Davids, Matthew
linked information resource: PI3K Inhibitors in Hematology: When One Door Closes….

Authorship 1663729
type: Authorship
author rank in publication: 15
linked author: Davids, Matthew
linked information resource: Chronic lymphocytic leukemia patients with chromosome 6q deletion as the sole cytogenetic abnormality display a high frequency of RPS15 mutations and have a poor prognosis.

Chronic lymphocytic leukemia patients with chromosome 6q deletion as the sole cytogenetic abnormality display a high frequency of RPS15 mutations and have a poor prognosis.
PubMed Identifier: 38949404
author list: Pérez Carretero C, González T, Quijada Álamo M, Rigolin GM, Dubuc A, Villaverde Ramiro Á, Rodríguez-Sánchez A, Rubio A, Dávila J, Vidal MJ, González Gascón Y Marín I, Hernández-Rivas JÁ, Benito R, Volpe V, Davids MS, Abramson JS, Cuneo A, Dal Cin P, Rodríguez-Vicente AE, Hernández-Rivas JM
published in: American journal of hematology
information resource reference: Chronic lymphocytic leukemia patients with chromosome 6q deletion as the sole cytogenetic abnormality display a high frequency of RPS15 mutations and have a poor prognosis. Am J Hematol. 2024 Sep; 99(9):1845-1848.
journal title abbreviation: Am J Hematol
publication date: 2024-07-01T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

PI3K Inhibitors in Hematology: When One Door Closes….
PubMed Identifier: 38967552
author list: Skånland SS, Okkenhaug K, Davids MS
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: PI3K Inhibitors in Hematology: When One Door Closes…. Clin Cancer Res. 2024 Sep 03; 30(17):3667-3675.
journal title abbreviation: Clin Cancer Res
publication date: 2024-09-03T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Assistant Professor of Medicine
is primary position: true
position in department: Medicine
position in division: Oncology
sort order: 1
type: Position
HR job title: Assistant Professor of Medicine
position in organization: Dana-Farber Cancer Institute

Instructor in Medicine
is primary position: true
position in department: Medicine
position in division: Oncology
sort order: 1
type: Position
HR job title: Instructor in Medicine
position in organization: Dana-Farber Cancer Institute

Associate Professor of Medicine
is primary position: true
position in department: Medicine
position in division: Oncology
sort order: 1
type: Position
HR job title: Associate Professor of Medicine
position in organization: Dana-Farber Cancer Institute

Research Associate in Medicine
is primary position: true
position in department: Medicine
position in division: Oncology
sort order: 1
type: Position
HR job title: Research Associate in Medicine
position in organization: Dana-Farber Cancer Institute

Professor of Medicine
is primary position: true
position in department: Medicine
position in division: Oncology
sort order: 1
type: Position
HR job title: Professor of Medicine
position in organization: Dana-Farber Cancer Institute

Associate Professor of Medicine
is primary position: true
position in department: Medicine
position in division: Oncology
sort order: 1
type: Position
HR job title: Associate Professor of Medicine
position in organization: Dana-Farber Cancer Institute

Professor of Medicine
is primary position: true
position in department: Medicine
position in division: Oncology
sort order: 1
type: Position
HR job title: Professor of Medicine
position in organization: Dana-Farber Cancer Institute

Authorship 1678034
type: Authorship
author rank in publication: 9
linked author: Davids, Matthew
linked information resource: LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclaxresistant chronic lymphocytic leukemia.

LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclaxresistant chronic lymphocytic leukemia.
PubMed Identifier: 39113656
author list: Ravikrishnan J, Diaz-Rohena DY, Muhowski E, Mo X, Lai TH, Misra S, Williams CD, Sanchez J, Mitchell A, Satpati S, Perry E, Kaufman T, Liu C, Lozanski A, Lozanski G, Rogers K, Kittai AS, Bhat SA, Collins MC, Davids MS, Jain N, Wierda WG, Lapalombella R, Byrd JC, Tan F, Chen Y, Chen Y, Shen Y, Anthony SP, Woyach JA, Sampath D
published in: Haematologica
information resource reference: LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclaxresistant chronic lymphocytic leukemia. Haematologica. 2025 Jan 01; 110(1):78-91.
journal title abbreviation: Haematologica
publication date: 2025-01-01T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Senior Lecturer on Medicine, Part-time
is primary position: true
position in department: Medicine
position in division: https://connects.catalyst.harvard.edu/Profiles/profile/1229413
sort order: 1
type: Position
HR job title: Senior Lecturer on Medicine, Part-time
position in organization: Dana-Farber Cancer Institute

Authorship 667952
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition.

Authorship 648465
type: Authorship
author rank in publication: 4
linked author: Davids, Matthew
linked information resource: A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.

A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
PubMed Identifier: 23645694
author list: Brown JR, Messmer B, Werner L, Davids MS, Mikler E, Supko JG, Fisher DC, LaCasce AS, Armand P, Jacobsen E, Dalton V, Tesar B, Fernandes SM, McDonough S, Ritz J, Rassenti L, Kipps TJ, Neuberg D, Freedman AS
published in: Haematologica
information resource reference: A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Haematologica. 2013 Jun; 98(6):964-70.
journal title abbreviation: Haematologica
publication date: 2013-05-03T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition.
PubMed Identifier: 23614795
author list: Davids MS, Letai A, Brown JR
published in: Leukemia & lymphoma
information resource reference: Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition. Leuk Lymphoma. 2013 Aug; 54(8):1823-5.
journal title abbreviation: Leuk Lymphoma
publication date: 2013-05-29T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1695401
type: Authorship
author rank in publication: 7
linked author: Davids, Matthew
linked information resource: Treatment patterns and burden of infection in patients with chronic lymphocytic leukemia and secondary immunodeficiency: a retrospective database study.

Authorship 1700879
type: Authorship
author rank in publication: 16
linked author: Davids, Matthew
linked information resource: Myeloid clonal hematopoiesis of indeterminate potential in patients with chronic lymphocytic leukemia.

Authorship 1702186
type: Authorship
author rank in publication: 18
linked author: Davids, Matthew
linked information resource: FoxO1/Rictor axis induces a nongenetic adaptation to ibrutinib via Akt activation in chronic lymphocytic leukemia.

Authorship 1694156
type: Authorship
author rank in publication: 20
linked author: Davids, Matthew
linked information resource: PI3Kd activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas.

Treatment patterns and burden of infection in patients with chronic lymphocytic leukemia and secondary immunodeficiency: a retrospective database study.
PubMed Identifier: 39264434
author list: Siffel C, Richter J, Anderson-Smits C, Kamieniak M, Ren K, Shah D, Davids MS
published in: Annals of hematology
information resource reference: Treatment patterns and burden of infection in patients with chronic lymphocytic leukemia and secondary immunodeficiency: a retrospective database study. Ann Hematol. 2024 Nov; 103(11):4567-4580.
journal title abbreviation: Ann Hematol
publication date: 2024-09-12T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

PI3Kd activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas.
PubMed Identifier: 39374583
author list: Arribas AJ, Napoli S, Gaudio E, Herbaux C, Cannas E, Tarantelli C, Bordone-Pittau R, Cascione L, Munz N, Aresu L, Sgrignani J, Rinaldi A, Kwee I, Rossi D, Cavalli A, Zucca E, Stussi G, Stathis A, Sloss C, Davids MS, Bertoni F
published in: Blood advances
information resource reference: PI3Kd activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas. Blood Adv. 2024 Dec 24; 8(24):6268-6281.
journal title abbreviation: Blood Adv
publication date: 2024-12-24T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Myeloid clonal hematopoiesis of indeterminate potential in patients with chronic lymphocytic leukemia.
PubMed Identifier: 39321421
author list: Vijenthira A, Volpe VO, Sekar A, Santos Azevedo R, Mikhaleva M, Gibson CJ, Martindale SP, Fardoun R, Tyekucheva S, Ren Y, Fernandes SM, Knisbacher BA, Hahn CK, Getz G, Wu CJ, Davids MS, Brown JR
published in: Blood advances
information resource reference: Myeloid clonal hematopoiesis of indeterminate potential in patients with chronic lymphocytic leukemia. Blood Adv. 2024 Dec 10; 8(23):5949-5956.
journal title abbreviation: Blood Adv
publication date: 2024-12-10T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

FoxO1/Rictor axis induces a nongenetic adaptation to ibrutinib via Akt activation in chronic lymphocytic leukemia.
PubMed Identifier: 39436708
author list: Ondrisova L, Seda V, Hlavac K, Pavelkova P, Hoferkova E, Chiodin G, Kostalova L, Mladonicka Pavlasova G, Filip D, Vecera J, Zeni PF, Oppelt J, Kahounova Z, Vichova R, Soucek K, Panovska A, Plevova K, Pospisilova S, Simkovic M, Vrbacky F, Lysak D, Fernandes SM, Davids MS, Maiques-Diaz A, Charalampopoulou S, Martin-Subero JI, Brown JR, Doubek M, Forconi F, Mayer J, Mraz M
published in: The Journal of clinical investigation
information resource reference: FoxO1/Rictor axis induces a nongenetic adaptation to ibrutinib via Akt activation in chronic lymphocytic leukemia. J Clin Invest. 2024 Oct 22; 134(23).
journal title abbreviation: J Clin Invest
publication date: 2024-10-22T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1708362
type: Authorship
author rank in publication: 10
linked author: Davids, Matthew
linked information resource: Investigating the influence of germline ATM variants in chronic lymphocytic leukemia on cancer vulnerability.

Investigating the influence of germline ATM variants in chronic lymphocytic leukemia on cancer vulnerability.
PubMed Identifier: 39568439
author list: Azevedo RS, Morelli F, Mashima K, Fardoun R, Tyekucheva S, Fernandes S, Shupe S, Terra M, Patel A, Davids MS, Yu J, Brown JR
published in: Haematologica
information resource reference: Investigating the influence of germline ATM variants in chronic lymphocytic leukemia on cancer vulnerability. Haematologica. 2025 Apr 01; 110(4):904-913.
journal title abbreviation: Haematologica
publication date: 2024-11-21T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Castillo, Jorge
eCommons Login: JC445
first name: Jorge
last name: Castillo
full name: Jorge Castillo, M.D.
has faculty rank: Associate Professor
photo: https://connects.catalyst.harvard.edu/Profiles/profile/Modules/CustomViewPersonGeneralInfo/PhotoHandler.ashx
Person ID: 121919
person in primary position: Associate Professor of Medicine
type: Agent
type: Person
preferred title: Associate Professor of Medicine

Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease.
PubMed Identifier: 39645236
author list: Davids MS, Ryan CE, Lampson BL, Ren Y, Tyekucheva S, Fernandes SM, Crombie JL, Kim AI, Weinstock M, Montegaard J, Walker HA, Greenman C, Patterson V, Jacobson CA, LaCasce AS, Armand P, Fisher DC, Lo S, Olszewski AJ, Arnason JE, Ahn IE, Brown JR
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease. J Clin Oncol. 2025 Mar; 43(7):788-799.
journal title abbreviation: J Clin Oncol
publication date: 2024-12-07T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study.
PubMed Identifier: 39698781
author list: Ghosh N, Eyre TA, Brown JR, Lamanna N, Manzoor BS, Coombs CC, Tuncer HH, Ujjani C, Leslie LA, Roeker LE, Davids MS, Rhodes JM, Skarbnik AP, Sinai W, Fleury I, Hill BT, Martinez-Calle N, Barr PM, Jawaid D, Emechebe N, Pearson L, Lansigan F, Choi Y, Jensen CE, Fakhri B, Stephens DM, Marx SE, Schuster SJ, Coyle M, Pivneva I, Watson T, Guerin A, Shadman M
published in: American journal of hematology
information resource reference: Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study. Am J Hematol. 2025 Mar; 100(3):511-515.
journal title abbreviation: Am J Hematol
publication date: 2024-12-19T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies.
PubMed Identifier: 39705540
author list: Davids MS, Brander DM, Alvarado-Valero Y, Diefenbach CS, Egan DN, Dinner SN, Javidi-Sharifi N, Al Malki MM, Begna KH, Bhatt VR, Abedin S, Cook RJ, Collins MC, Roleder C, Dominguez EC, Rajagopalan P, Wiley SE, Ghalie RG, Danilov AV
published in: Blood advances
information resource reference: A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies. Blood Adv. 2025 Feb 25; 9(4):820-832.
journal title abbreviation: Blood Adv
publication date: 2025-02-25T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition.
PubMed Identifier: 39806516
author list: Glaviano A, Lau HS, Carter LM, Lee EHC, Lam HY, Okina E, Tan DJJ, Tan W, Ang HL, Carbone D, Yee MY, Shanmugam MK, Huang XZ, Sethi G, Tan TZ, Lim LHK, Huang RY, Ungefroren H, Giovannetti E, Tang DG, Bruno TC, Luo P, Andersen MH, Qian BZ, Ishihara J, Radisky DC, Elias S, Yadav S, Kim M, Robert C, Diana P, Schalper KA, Shi T, Merghoub T, Krebs S, Kusumbe AP, Davids MS, Brown JR, Kumar AP
published in: Journal of hematology & oncology
information resource reference: Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition. J Hematol Oncol. 2025 Jan 13; 18(1):6.
journal title abbreviation: J Hematol Oncol
publication date: 2025-01-13T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Long-term results of a phase 1/1b study of ibrutinib plus umbralisib for relapsed/refractory chronic lymphocytic leukemia.
PubMed Identifier: 39816532
author list: Ryan CE, Ren Y, Tyekucheva S, Arnason JE, Boruchov AM, Jacobson CA, Fisher DC, Miskin H, Sportelli P, Brown JR, Davids MS
published in: HemaSphere
information resource reference: Long-term results of a phase 1/1b study of ibrutinib plus umbralisib for relapsed/refractory chronic lymphocytic leukemia. Hemasphere. 2025 Jan; 9(1):e70067.
journal title abbreviation: Hemasphere
publication date: 2025-01-15T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1716366
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies.

Authorship 1718601
type: Authorship
author rank in publication: 37
linked author: Davids, Matthew
linked information resource: Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition.

Authorship 1715041
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease.

Authorship 1716085
type: Authorship
author rank in publication: 11
linked author: Davids, Matthew
linked information resource: Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study.

Authorship 1722503
type: Authorship
author rank in publication: 11
linked author: Davids, Matthew
linked information resource: Long-term results of a phase 1/1b study of ibrutinib plus umbralisib for relapsed/refractory chronic lymphocytic leukemia.

Authorship 674482
type: Authorship
author rank in publication: 11
linked author: Davids, Matthew
linked information resource: Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma.

Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma.
PubMed Identifier: 23795711
author list: Armand P, Oki Y, Neuberg DS, Faham M, Cummings C, Klinger M, Weng L, Bhattar S, Lacasce AS, Jacobsen ED, Davids MS, Jacobson C, Fisher DC, Brown JR, Fowler NH, Alma Rodriguez M, Wallace MJ, Neelapu SS, Rodig S, Younes A, Freedman AS
published in: British journal of haematology
information resource reference: Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2013 Oct; 163(1):123-6.
journal title abbreviation: Br J Haematol
publication date: 2013-06-25T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

BCL-2 dependence is a favorable predictive marker of response to therapy for chronic lymphocytic leukemia.
PubMed Identifier: 40025512
author list: Chong SJF, Lu J, Valentin R, Lehmberg TZ, Eu JQ, Wang J, Zhu F, Kong LR, Fernandes SM, Zhang J, Herbaux C, Goh BC, Brown JR, Niemann CU, Huber W, Zenz T, Davids MS
published in: Molecular cancer
information resource reference: BCL-2 dependence is a favorable predictive marker of response to therapy for chronic lymphocytic leukemia. Mol Cancer. 2025 Mar 03; 24(1):62.
journal title abbreviation: Mol Cancer
publication date: 2025-03-03T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Large-scale dependency and drug screens to characterize the therapeutic vulnerabilities of multiple myeloma with 1q.
PubMed Identifier: 40073369
author list: Sklavenitis-Pistofidis R, Lightbody ED, Reidy M, Tsuji J, Alberge JB, Aranha MP, Heilpern-Mallory D, Roweth HG, Huynh D, Chong SJF, Chung AY, Zhang J, Hackett L, Haradhvala NJ, Wu T, Su NK, Berrios B, Belkin S, Dutta AK, Knudson RA, Brandt C, Greipp PT, Davids MS, Papaioannou M, Getz G, Ghobrial IM, Manier S
published in: Blood
information resource reference: Large-scale dependency and drug screens to characterize the therapeutic vulnerabilities of multiple myeloma with 1q. Blood. 2025 Jul 03; 146(1):89-103.
journal title abbreviation: Blood
publication date: 2025-07-03T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1735956
type: Authorship
author rank in publication: 11
linked author: Davids, Matthew
linked information resource: Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL.

Authorship 1731064
type: Authorship
author rank in publication: 17
linked author: Davids, Matthew
linked information resource: BCL-2 dependence is a favorable predictive marker of response to therapy for chronic lymphocytic leukemia.

Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL.
PubMed Identifier: 39979241
author list: Kittai AS, Huang Y, Miller S, Allan JN, Bhat SA, Bond DA, Brander DM, Byrd JC, Chavez JC, Chong E, Davids MS, Danilov AV, Ding W, Dowling MR, Dvorak-Kornaus K, Freedman H, Hampel PJ, Ho C, Hwang SR, Islam P, Malakhov N, Matasar M, Miller C, Omer Z, Parikh SA, Parry E, Rabe KG, Raess PW, Rai M, Roeker L, Rhodes J, Rogers KA, Saha A, Schade J, Scott HW, Shadman M, Shouse G, Skarbnik A, Spurgeon S, Stephens DM, Thompson MC, Thompson PA, Wang Y, Yano M, Woyach JA
published in: Blood cancer journal
information resource reference: Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL. Blood Cancer J. 2025 Feb 20; 15(1):23.
journal title abbreviation: Blood Cancer J
publication date: 2025-02-20T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1740119
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: ZUMA-8: a phase 1 study of brexucabtagene autoleucel in patients with relapsed/refractory chronic lymphocytic leukemia.

Authorship 1741174
type: Authorship
author rank in publication: 6
linked author: Davids, Matthew
linked information resource: International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations.

Authorship 1745974
type: Authorship
author rank in publication: 10
linked author: Davids, Matthew
linked information resource: Development of a robust BH3 drug toolkit for precision medicine in hematologic malignancies.

Authorship 1745210
type: Authorship
author rank in publication: 23
linked author: Davids, Matthew
linked information resource: Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia.

Authorship 1749357
type: Authorship
author rank in publication: 23
linked author: Davids, Matthew
linked information resource: Large-scale dependency and drug screens to characterize the therapeutic vulnerabilities of multiple myeloma with 1q.

Authorship 1750875
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: Erratum: Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease.

Development of a robust BH3 drug toolkit for precision medicine in hematologic malignancies.
PubMed Identifier: 40365276
author list: Jacquier V, Romero A, Molinaro C, Somayaji R, Abouladze M, Gadacha OK, Ovejero S, de Boussac H, Gabellier L, Davids MS, Moreaux J, Herbaux C
published in: Theranostics
information resource reference: Development of a robust BH3 drug toolkit for precision medicine in hematologic malignancies. Theranostics. 2025; 15(12):5705-5718.
journal title abbreviation: Theranostics
publication date: 2025-04-21T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Erratum: Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease.
PubMed Identifier: 40101168
author list: Davids MS, Ryan CE, Lampson BL, Ren Y, Tyekucheva S, Fernandes SM, Crombie JL, Kim AI, Weinstock M, Montegaard J, Walker HA, Greenman C, Patterson V, Jacobson CA, LaCasce AS, Armand P, Fisher DC, Lo S, Olszewski AJ, Arnason JE, Ahn IE, Brown JR
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Erratum: Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease. J Clin Oncol. 2025 Apr 20; 43(12):1521-1522.
journal title abbreviation: J Clin Oncol
publication date: 2025-03-18T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

ZUMA-8: a phase 1 study of brexucabtagene autoleucel in patients with relapsed/refractory chronic lymphocytic leukemia.
PubMed Identifier: 40209059
author list: Davids MS, Kenderian SS, Flinn I, Hill BT, Maris M, Ghia P, Byrne M, Bartlett NL, Pagel JM, Zheng Y, Kanska J, Zhang W, Granados E, Pinilla-Ibarz J
published in: Blood
information resource reference: ZUMA-8: a phase 1 study of brexucabtagene autoleucel in patients with relapsed/refractory chronic lymphocytic leukemia. Blood. 2025 Aug 21; 146(8):938-943.
journal title abbreviation: Blood
publication date: 2025-08-21T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia.
PubMed Identifier: 40179394
author list: Yoon JT, Zhou Y, Mikhaleva M, Choi DS, Fernandes SM, Armand P, Bessnow AC, Crombie JL, Fisher DC, Jacobsen ED, Jacobson CA, Kim AI, LaCasce AS, Merryman RW, Odejide OO, Parry EM, Qualls DA, Ryan CE, Sekar A, Soumerai JD, Arnason J, Tyekucheva S, Davids MS, Brown JR, Ahn IE
published in: Blood advances
information resource reference: Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia. Blood Adv. 2025 Jun 10; 9(11):2808-2817.
journal title abbreviation: Blood Adv
publication date: 2025-06-10T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations.
PubMed Identifier: 40239121
author list: Kittai AS, Marchetti M, Al-Sawaf O, Benjamini O, Danilov AV, Davids MS, Eichhorst B, Eyre TA, Frustaci AM, Hallek M, Hampel PJ, Herishanu Y, Hicks RJ, Kater AP, King RL, Martin-Subero JI, Owen C, Parry E, Ponzoni M, Rossi D, Siddiqi T, Stilgenbauer S, Tam CS, Hacken ET, Thompson PA, Wierda W, Gaidano G, Woyach JA, Ghia P
published in: Blood
information resource reference: International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations. Blood. 2025 Jul 17; 146(3):291-303.
journal title abbreviation: Blood
publication date: 2025-07-17T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 204302
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic Merkel cell carcinoma.

Mutations and translocations associated with venetoclax resistance in chronic lymphocytic leukemia.
PubMed Identifier: 40550846
author list: Mashima K, Kuang Y, Fernandes SM, Xu S, Hanna B, Shupe S, Mikhaleva M, Santos RA, Predko P, Fardoun R, Bidgoli A, Martindale SP, Naeem A, Davids MS, Paweletz C, Brown JR
published in: Leukemia
information resource reference: Mutations and translocations associated with venetoclax resistance in chronic lymphocytic leukemia. Leukemia. 2025 Aug; 39(8):2026-2029.
journal title abbreviation: Leukemia
publication date: 2025-06-23T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 722663
type: Authorship
author rank in publication: 4
linked author: Davids, Matthew
linked information resource: Association of advanced leukemic stage and skin cancer tumor stage with poor skin cancer outcomes in patients with chronic lymphocytic leukemia.

Authorship 721547
type: Authorship
author rank in publication: 2
linked author: Davids, Matthew
linked information resource: Fatty intra-abdominal lymph nodes in chronic lymphocytic leukemia.

Authorship 723353
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: Boldly Targeting Kinases without mutations.

Fatty intra-abdominal lymph nodes in chronic lymphocytic leukemia.
PubMed Identifier: 24123185
author list: Cooley CL, Davids MS, Giardino A
published in: American journal of hematology
information resource reference: Fatty intra-abdominal lymph nodes in chronic lymphocytic leukemia. Am J Hematol. 2014 Feb; 89(2):234-5.
journal title abbreviation: Am J Hematol
publication date: 2014-02-01T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Association of advanced leukemic stage and skin cancer tumor stage with poor skin cancer outcomes in patients with chronic lymphocytic leukemia.
PubMed Identifier: 24429548
author list: Velez NF, Karia PS, Vartanov AR, Davids MS, Brown JR, Schmults CD
published in: JAMA dermatology
information resource reference: Association of advanced leukemic stage and skin cancer tumor stage with poor skin cancer outcomes in patients with chronic lymphocytic leukemia. JAMA Dermatol. 2014 Mar; 150(3):280-7.
journal title abbreviation: JAMA Dermatol
publication date: 2014-03-01T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Boldly Targeting Kinases without mutations.
PubMed Identifier: 24558189
author list: Davids MS
published in: Blood
information resource reference: Boldly Targeting Kinases without mutations. Blood. 2014 Feb 20; 123(8):1119-21.
journal title abbreviation: Blood
publication date: 2014-02-20T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Is Bcl-2 a valid target in the treatment of indolent non-Hodgkin lymphoma?
PubMed Identifier: 24794805
author list: Brem EA, Davids MS
published in: Leukemia & lymphoma
information resource reference: Is Bcl-2 a valid target in the treatment of indolent non-Hodgkin lymphoma? Leuk Lymphoma. 2014 Dec; 55(12):2675-7.
journal title abbreviation: Leuk Lymphoma
publication date: 2014-06-27T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 178877
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: Medical management of radiation victims in the United States.

Authorship 1783000
type: Authorship
author rank in publication: 14
linked author: Davids, Matthew
linked information resource: Mutations and translocations associated with venetoclax resistance in chronic lymphocytic leukemia.

Authorship 735510
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase.

Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase.
PubMed Identifier: 24941982
author list: Davids MS, Brown JR
published in: Future oncology (London, England)
information resource reference: Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase. Future Oncol. 2014 May; 10(6):957-67.
journal title abbreviation: Future Oncol
publication date: 2014-05-01T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1792689
type: Authorship
author rank in publication: 23
linked author: Davids, Matthew
linked information resource: State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee.

Authorship 1793503
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: Safety, tolerability, and pharmacokinetics of lisaftoclax (APG-2575)-based therapy in patients with chronic lymphocytic leukemia: Phase 1b/2 study.

Authorship 1794409
type: Authorship
author rank in publication: 16
linked author: Davids, Matthew
linked information resource: Integrating single-cell biophysical and transcriptomic features to resolve functional heterogeneity in mantle cell lymphoma.

Authorship 1808945
type: Authorship
author rank in publication: 2
linked author: Davids, Matthew
linked information resource: Advances in the Management of Relapsed/Refractory CLL and Richter Transformation.

Authorship 1813423
type: Authorship
author rank in publication: 12
linked author: Davids, Matthew
linked information resource: Clinical Outcomes in Patients With CLL Treated With BTKi at a Large US Cancer Center.

Authorship 1813993
type: Authorship
author rank in publication: 2
linked author: Davids, Matthew
linked information resource: Multiple Myeloma and Secondary Immunodeficiency: A Retrospective Database Analysis Assessing Burden of Infection and Treatment Patterns.

Authorship 1813802
type: Authorship
author rank in publication: 2
linked author: Davids, Matthew
linked information resource: Acalabrutinib to assail CLL in the frail.

Authorship 1815337
type: Authorship
author rank in publication: 2
linked author: Davids, Matthew
linked information resource: How I treat patients with CLL after prior treatment with a covalent BTK inhibitor and a BCL-2 inhibitor.

Authorship 1816365
type: Authorship
author rank in publication: 10
linked author: Davids, Matthew
linked information resource: Evaluating complete response/remission rate as a surrogate endpoint in relapsed/refractory chronic lymphocytic leukemia.

Authorship 1817725
type: Authorship
author rank in publication: 12
linked author: Davids, Matthew
linked information resource: Ipilimumab with and without nivolumab in patients with classic Hodgkin lymphoma with progression after PD-1 blockade.

Authorship 1823809
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: Real-world characteristics, treatment patterns, and outcomes of patients with 2 or more LOTs for CLL/SLL in the United States.

Authorship 1824990
type: Authorship
author rank in publication: 2
linked author: Davids, Matthew
linked information resource: The Rapidly Evolving Landscape of the Biology and Therapy of Chronic Lymphocytic Leukemia.

Authorship 1825942
type: Authorship
author rank in publication: 14
linked author: Davids, Matthew
linked information resource: The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia.

Authorship 1829889
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: BRUIN 313 and 314 Trials Open the Door for Noncovalent Bruton Tyrosine Kinase Inhibition as Initial Therapy for Chronic Lymphocytic Leukemia.

Authorship 1831495
type: Authorship
author rank in publication: 51
linked author: Davids, Matthew
linked information resource: Central nervous system involvement in CLL: an international retrospective study by ERIC, the European Research Initiative on CLL.

Authorship 1834475
type: Authorship
author rank in publication: 12
linked author: Davids, Matthew
linked information resource: Efficacy of Pirtobrutinib Monotherapy in Treatment-Naïve Chronic Lymphocytic Leukemia: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.

Authorship 1833924
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: First-line treatment for CLL in the era of targeted therapy.

Authorship 1834840
type: Authorship
author rank in publication: 20
linked author: Davids, Matthew
linked information resource: Targeting ß-catenin degradation with GSK3ß inhibitors induces cell death in acute lymphoblastic leukemia.

Authorship 1846069
type: Authorship
author rank in publication: 2
linked author: Davids, Matthew
linked information resource: Triplet Therapies in Chronic Lymphocytic Leukemia.

Authorship 1846083
type: Authorship
author rank in publication: 14
linked author: Davids, Matthew
linked information resource: Superoxide-mediated phosphorylation and stabilization of Mcl-1 by AKT underlie venetoclax resistance in hematologic malignancies.

Authorship 1848072
type: Authorship
author rank in publication: 14
linked author: Davids, Matthew
linked information resource: Mechanisms of immune escape and extramedullary tropism in leukemia cutis.

Advances in the Management of Relapsed/Refractory CLL and Richter Transformation.
PubMed Identifier: 40517442
author list: Javidi-Sharifi N, Davids MS
published in: Hematological oncology
information resource reference: Advances in the Management of Relapsed/Refractory CLL and Richter Transformation. Hematol Oncol. 2025 Jun; 43 Suppl 2:e70064.
journal title abbreviation: Hematol Oncol
publication date: 2025-06-01T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Acalabrutinib to assail CLL in the frail.
PubMed Identifier: 41447452
author list: Ryan CE, Davids MS
published in: Blood
information resource reference: Acalabrutinib to assail CLL in the frail. Blood. 2025 Dec 25; 146(26):3131-3132.
journal title abbreviation: Blood
publication date: 2025-12-25T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Real-world characteristics, treatment patterns, and outcomes of patients with 2 or more LOTs for CLL/SLL in the United States.
PubMed Identifier: 40546723
author list: Davids MS, Ambrose J, de Nigris E, Prescott J, Leng S, Farooqui MZH, Gandra SR, Zettler CM, Fernandes LL, Wang CK, Shadman M
published in: Blood neoplasia
information resource reference: Real-world characteristics, treatment patterns, and outcomes of patients with 2 or more LOTs for CLL/SLL in the United States. Blood Neoplasia. 2025 Feb; 2(1):100047.
journal title abbreviation: Blood Neoplasia
publication date: 2024-10-14T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Triplet Therapies in Chronic Lymphocytic Leukemia.
PubMed Identifier: 40707323
author list: Soumerai JD, Davids MS
published in: Hematology/oncology clinics of North America
information resource reference: Triplet Therapies in Chronic Lymphocytic Leukemia. Hematol Oncol Clin North Am. 2025 Oct; 39(5):903-915.
journal title abbreviation: Hematol Oncol Clin North Am
publication date: 2025-07-23T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

The Rapidly Evolving Landscape of the Biology and Therapy of Chronic Lymphocytic Leukemia.
PubMed Identifier: 40675857
author list: Brown JR, Davids MS
published in: Hematology/oncology clinics of North America
information resource reference: The Rapidly Evolving Landscape of the Biology and Therapy of Chronic Lymphocytic Leukemia. Hematol Oncol Clin North Am. 2025 Oct; 39(5):xiii-xiv.
journal title abbreviation: Hematol Oncol Clin North Am
publication date: 2025-07-16T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

How I treat patients with CLL after prior treatment with a covalent BTK inhibitor and a BCL-2 inhibitor.
PubMed Identifier: 40729699
author list: Shadman M, Davids MS
published in: Blood
information resource reference: How I treat patients with CLL after prior treatment with a covalent BTK inhibitor and a BCL-2 inhibitor. Blood. 2025 Oct 23; 146(17):2029-2036.
journal title abbreviation: Blood
publication date: 2025-10-23T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Superoxide-mediated phosphorylation and stabilization of Mcl-1 by AKT underlie venetoclax resistance in hematologic malignancies.
PubMed Identifier: 40707672
author list: Chong SJF, Lai JXH, Iskandar K, Leong BJ, Wang C, Wang Y, Guièze R, Raman D, Lim RHF, Wu CJ, Chng WJ, Cheung AMS, Chuah C, Davids MS, Pervaiz S
published in: Leukemia
information resource reference: Superoxide-mediated phosphorylation and stabilization of Mcl-1 by AKT underlie venetoclax resistance in hematologic malignancies. Leukemia. 2025 Oct; 39(10):2477-2491.
journal title abbreviation: Leukemia
publication date: 2025-07-24T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Safety, tolerability, and pharmacokinetics of lisaftoclax (APG-2575)-based therapy in patients with chronic lymphocytic leukemia: Phase 1b/2 study.
PubMed Identifier: 41109219
author list: Davids MS, Chanan-Khan A, Ailawadhi S, Ivanov V, Usenko G, Nogaieva L, Kryachock I, Muzhychuk I, Perekhrestenko T, Kyselova O, Myasnikov A, Lukavetskyy L, Uspenskaya O, Marlton P, Proydakov A, Borisenkova E, Winter A, Siddiqi T, Lysa T, Bakirov B, Gabrail N, Ganju V, Konstantinova T, Samoilova O, Karpenko O, Osipov I, Mudenda B, Fu T, Chen Z, Liang Z, Mekala DJ, Li M, Glass L, Ahmad M, De A, Shah V, Wang H, Winkler RE, Yang D, Zhai Y
published in: Med (New York, N.Y.)
information resource reference: Safety, tolerability, and pharmacokinetics of lisaftoclax (APG-2575)-based therapy in patients with chronic lymphocytic leukemia: Phase 1b/2 study. Med. 2025 Dec 12; 6(12):100885.
journal title abbreviation: Med
publication date: 2025-10-17T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Integrating single-cell biophysical and transcriptomic features to resolve functional heterogeneity in mantle cell lymphoma.
PubMed Identifier: 41348872
author list: Zhang Y, Debaize L, Langenbucher A, Weekes J, Vogiatzi I, Miettinen TP, Zhang M, Sumpena E, Liu H, Duquette SM, Hackett L, Zhang J, Baghiyan S, Redd RA, Aryee M, Davids MS, Kim AI, Ryan CE, Weinstock DM, Manalis SR, Murakami MA
published in: Science advances
information resource reference: Integrating single-cell biophysical and transcriptomic features to resolve functional heterogeneity in mantle cell lymphoma. Sci Adv. 2025 Dec 05; 11(49):eady2963.
journal title abbreviation: Sci Adv
publication date: 2025-12-05T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee.
PubMed Identifier: 40883275
author list: Ryan CE, Ahn IE, Sekar A, Rawstron A, Almeida J, Martin-Subero I, Parry EM, Alcoceba M, Calado DP, Orfao A, Langerak AW, Veelken H, Langerbeins P, Stephens DM, Parikh SA, Niemann CU, Roulland S, Stamatopoulos K, Slager SL, Shanafelt T, Ghia P, Okosun J, Davids MS
published in: Blood cancer journal
information resource reference: State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee. Blood Cancer J. 2025 Aug 29; 15(1):148.
journal title abbreviation: Blood Cancer J
publication date: 2025-08-29T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia.
PubMed Identifier: 40809193
author list: Alvarado-Valero Y, Cook RJ, Dinner SN, Keng M, Begna KH, Javidi-Sharifi N, Abedin S, Al Malki MM, Bhatt VR, Rajagopalan P, Tang M, Wiley SE, Ghalie RG, Davids MS
published in: Blood neoplasia
information resource reference: The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia. Blood Neoplasia. 2025 Aug; 2(3):100108.
journal title abbreviation: Blood Neoplasia
publication date: 2025-04-25T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Evaluating complete response/remission rate as a surrogate endpoint in relapsed/refractory chronic lymphocytic leukemia.
PubMed Identifier: 41067186
author list: Wang L, Kurt M, Disher T, Liu FF, Craigie S, Perna SK, Aronitz E, Eyre TA, Ysebaert L, Davids MS
published in: Leukemia research
information resource reference: Evaluating complete response/remission rate as a surrogate endpoint in relapsed/refractory chronic lymphocytic leukemia. Leuk Res. 2025 Nov; 158:108113.
journal title abbreviation: Leuk Res
publication date: 2025-09-27T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Mechanisms of immune escape and extramedullary tropism in leukemia cutis.
PubMed Identifier: 41026928
author list: Penter L, Maurer K, Cieri N, Lu WS, Lyu H, Selig M, Joosten M, Ihlow J, Li S, Livak KJ, Bullinger L, Ritz J, Bachireddy P, Davids MS, Garcia JS, Soiffer RJ, Wu CJ
published in: Blood
information resource reference: Mechanisms of immune escape and extramedullary tropism in leukemia cutis. Blood. 2026 Jan 01; 147(1):35-47.
journal title abbreviation: Blood
publication date: 2026-01-01T00:00:00
year: 2026
type: Academic Article
type: Article
type: Document
type: Information Resource

Ipilimumab with and without nivolumab in patients with classic Hodgkin lymphoma with progression after PD-1 blockade.
PubMed Identifier: 41438597
author list: Merryman RW, Kline J, Redd RA, Olszewski H, Welsh E, Pfaff K, Lee H, McDonough M, Ahn IE, Brown JR, Crombie JL, Davids MS, Fisher DC, Jacobsen ED, Jacobson CA, Kim AI, Odejide OO, Parry EM, Ryan CE, Shipp MA, Armand P, Rodig S, Abramson JS, LaCasce AS
published in: Blood neoplasia
information resource reference: Ipilimumab with and without nivolumab in patients with classic Hodgkin lymphoma with progression after PD-1 blockade. Blood Neoplasia. 2026 Feb; 3(1):100173.
journal title abbreviation: Blood Neoplasia
publication date: 2025-10-09T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Central nervous system involvement in CLL: an international retrospective study by ERIC, the European Research Initiative on CLL.
PubMed Identifier: 41135013
author list: Chatzikonstantinou T, Mikhaleva M, Brieghel C, Papangelou C, Minga E, Arrais-Rodrigues C, Besikli-Dimou S, Cerutti A, Doubek M, Enggaard L, Espinet B, Ferrer-Lores B, Garcia Vela JA, Gentile M, Vázquez EG, Gutwein O, Herishanu Y, Jablonowska-Babij P, Jaksic O, Josefsson P, Kalicinska E, Kislova M, Lista E, Kotsianidis I, Marquet J, Martino EA, McAuley C, Mela Osorio MJ, Moia R, Mosquera C, Nikitin E, Pavlovsky MA, Pfister V, Savas EM, Scarfò L, Sever M, Shvidel L, Simkovic M, Stavroyianni N, Talimtzi P, Tranidou A, Visentin A, Vrachiolias G, Wasik-Szczepanek E, Wróbel T, Yagci M, Cellini A, Chatzidimitriou A, Gaidano G, Anderson MA, Davids MS, Brown JR, Niemann CU, Stamatopoulos K, Ghia P, Ahn IE, Koren-Michowitz M
published in: Blood advances
information resource reference: Central nervous system involvement in CLL: an international retrospective study by ERIC, the European Research Initiative on CLL. Blood Adv. 2026 Jan 27; 10(2):428-438.
journal title abbreviation: Blood Adv
publication date: 2026-01-27T00:00:00
year: 2026
type: Academic Article
type: Article
type: Document
type: Information Resource

BRUIN 313 and 314 Trials Open the Door for Noncovalent Bruton Tyrosine Kinase Inhibition as Initial Therapy for Chronic Lymphocytic Leukemia.
PubMed Identifier: 41363770
author list: Davids MS
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: BRUIN 313 and 314 Trials Open the Door for Noncovalent Bruton Tyrosine Kinase Inhibition as Initial Therapy for Chronic Lymphocytic Leukemia. J Clin Oncol. 2026 Feb 20; 44(6):435-439.
journal title abbreviation: J Clin Oncol
publication date: 2025-12-09T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Clinical Outcomes in Patients With CLL Treated With BTKi at a Large US Cancer Center.
PubMed Identifier: 41328215
author list: Lin KH, Huynh L, Yang X, Zanardo E, Liborski D, McDonough MM, Farooqui MZH, De Nigris E, Gandra SR, Duh MS, Brown JR, Davids MS
published in: Advances in hematology
information resource reference: Clinical Outcomes in Patients With CLL Treated With BTKi at a Large US Cancer Center. Adv Hematol. 2025; 2025:7492594.
journal title abbreviation: Adv Hematol
publication date: 2025-11-30T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Targeting ß-catenin degradation with GSK3ß inhibitors induces cell death in acute lymphoblastic leukemia.
PubMed Identifier: 41507538
author list: Cosgun KN, Jumaa H, Robinson ME, Cheng Z, Oulghazi S, Kume K, Fonseca Arce D, Agadzhanian N, Kistner KM, Leveille E, Drivet E, Yu F, Qian Z, Song JY, Chan WC, Xu L, Xiao G, Taketo MM, Kothari S, Davids MS, Schjerven H, Jellusova J, Müschen M
published in: Nature cancer
information resource reference: Targeting ß-catenin degradation with GSK3ß inhibitors induces cell death in acute lymphoblastic leukemia. Nat Cancer. 2026 Jan; 7(1):150-168.
journal title abbreviation: Nat Cancer
publication date: 2026-01-08T00:00:00
year: 2026
type: Academic Article
type: Article
type: Document
type: Information Resource

Multiple Myeloma and Secondary Immunodeficiency: A Retrospective Database Analysis Assessing Burden of Infection and Treatment Patterns.
PubMed Identifier: 41458534
author list: Siffel C, Davids MS, Anderson-Smits C, Kamieniak M, Ren K, Ardeshir-Rouhani-Fard S, Shah D, Richter J
published in: Advances in hematology
information resource reference: Multiple Myeloma and Secondary Immunodeficiency: A Retrospective Database Analysis Assessing Burden of Infection and Treatment Patterns. Adv Hematol. 2025; 2025:5340241.
journal title abbreviation: Adv Hematol
publication date: 2025-12-25T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

First-line treatment for CLL in the era of targeted therapy.
PubMed Identifier: 41507154
author list: Davids MS, Stilgenbauer S, Tam CS
published in: Blood cancer journal
information resource reference: First-line treatment for CLL in the era of targeted therapy. Blood Cancer J. 2026 Jan 08; 16(1):19.
journal title abbreviation: Blood Cancer J
publication date: 2026-01-08T00:00:00
year: 2026
type: Academic Article
type: Article
type: Document
type: Information Resource

Efficacy of Pirtobrutinib Monotherapy in Treatment-Naïve Chronic Lymphocytic Leukemia: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
PubMed Identifier: 41749915
author list: Eyre TA, Hess LM, Masoudi E, Jen MH, Abhyankar S, Graham-Clarke PL, Bhandari NR, Maguire P, Winfree KB, Tracey M, Taipale KL, Davids MS
published in: Cancers
information resource reference: Efficacy of Pirtobrutinib Monotherapy in Treatment-Naïve Chronic Lymphocytic Leukemia: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. Cancers (Basel). 2026 Feb 18; 18(4).
journal title abbreviation: Cancers (Basel)
publication date: 2026-02-18T00:00:00
year: 2026
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 742576
type: Authorship
author rank in publication: 2
linked author: Davids, Matthew
linked information resource: Selective Bcl-2 inhibition to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma.

Selective Bcl-2 inhibition to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma.
PubMed Identifier: 25003352
author list: Ng SY, Davids MS
published in: Clinical advances in hematology & oncology : H&O
information resource reference: Selective Bcl-2 inhibition to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma. Clin Adv Hematol Oncol. 2014 Apr; 12(4):224-9.
journal title abbreviation: Clin Adv Hematol Oncol
publication date: 2014-04-01T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 755504
type: Authorship
author rank in publication: 7
linked author: Davids, Matthew
linked information resource: Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation.

Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation.
PubMed Identifier: 24859877
author list: Murase K, Kim HT, Bascug OR, Kawano Y, Ryan J, Matsuoka K, Davids MS, Koreth J, Ho VT, Cutler C, Armand P, Alyea EP, Blazar BR, Antin JH, Soiffer RJ, Letai A, Ritz J
published in: Haematologica
information resource reference: Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. Haematologica. 2014 Sep; 99(9):1499-508.
journal title abbreviation: Haematologica
publication date: 2014-05-23T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 75970
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: Assessing surge capacity for radiation victims with marrow toxicity.

Authorship 776319
type: Authorship
author rank in publication: 2
linked author: Davids, Matthew
linked information resource: Is Bcl-2 a valid target in the treatment of indolent non-Hodgkin lymphoma?

Authorship 73051
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: Serum free light chain analysis.

Authorship 552991
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: The molecular pathogenesis of myelodysplastic syndromes.

Authorship 228715
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: Targeting the B cell receptor pathway in chronic lymphocytic leukemia.

Authorship 260095
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: Targeting the B-cell lymphoma/leukemia 2 family in cancer.

Authorship 392688
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: STK25 is a candidate gene for pseudopseudohypoparathyroidism.

Authorship 789057
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: The evolving role of hematopoietic cell transplantation in chronic lymphocytic leukemia.

The evolving role of hematopoietic cell transplantation in chronic lymphocytic leukemia.
PubMed Identifier: 25682168
author list: Davids MS, Alyea EP
published in: Current hematologic malignancy reports
information resource reference: The evolving role of hematopoietic cell transplantation in chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2015 Mar; 10(1):18-27.
journal title abbreviation: Curr Hematol Malig Rep
publication date: 2015-03-01T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 812915
type: Authorship
author rank in publication: 10
linked author: Davids, Matthew
linked information resource: The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells.

The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells.
PubMed Identifier: 25582069
author list: Cao Y, Yang G, Hunter ZR, Liu X, Xu L, Chen J, Tsakmaklis N, Hatjiharissi E, Kanan S, Davids MS, Castillo JJ, Treon SP
published in: British journal of haematology
information resource reference: The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells. Br J Haematol. 2015 Jul; 170(1):134-8.
journal title abbreviation: Br J Haematol
publication date: 2015-01-12T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 816242
type: Authorship
author rank in publication: 2
linked author: Davids, Matthew
linked information resource: Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma.

Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma.
PubMed Identifier: 25840972
author list: Brown JR, Davids MS, Rodon J, Abrisqueta P, Kasar SN, Lager J, Jiang J, Egile C, Awan FT
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma. Clin Cancer Res. 2015 Jul 15; 21(14):3160-9.
journal title abbreviation: Clin Cancer Res
publication date: 2015-04-03T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 823900
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: Controversial fluorescence in situ hybridization cytogenetic abnormalities in chronic lymphocytic leukaemia: new insights from a large cohort.

Controversial fluorescence in situ hybridization cytogenetic abnormalities in chronic lymphocytic leukaemia: new insights from a large cohort.
PubMed Identifier: 26032737
author list: Davids MS, Vartanov A, Werner L, Neuberg D, Dal Cin P, Brown JR
published in: British journal of haematology
information resource reference: Controversial fluorescence in situ hybridization cytogenetic abnormalities in chronic lymphocytic leukaemia: new insights from a large cohort. Br J Haematol. 2015 Sep; 170(5):694-703.
journal title abbreviation: Br J Haematol
publication date: 2015-06-01T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 847251
type: Authorship
author rank in publication: 2
linked author: Davids, Matthew
linked information resource: BCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of Apoptosis.

BCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of Apoptosis.
PubMed Identifier: 26567361
author list: Gibson CJ, Davids MS
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: BCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of Apoptosis. Clin Cancer Res. 2015 Nov 15; 21(22):5021-9.
journal title abbreviation: Clin Cancer Res
publication date: 2015-11-15T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Inhibition of the Bruton Tyrosine Kinase Pathway in B-Cell Lymphoproliferative Disorders.
PubMed Identifier: 26841015
author list: Castillo JJ, Treon SP, Davids MS
published in: Cancer journal (Sudbury, Mass.)
information resource reference: Inhibition of the Bruton Tyrosine Kinase Pathway in B-Cell Lymphoproliferative Disorders. Cancer J. 2016 Jan-Feb; 22(1):34-9.
journal title abbreviation: Cancer J
publication date: 2016-01-01T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 862595
type: Authorship
author rank in publication: 2
linked author: Davids, Matthew
linked information resource: Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women.

Authorship 863772
type: Authorship
author rank in publication: 2
linked author: Davids, Matthew
linked information resource: Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

Authorship 868384
type: Authorship
author rank in publication: 3
linked author: Davids, Matthew
linked information resource: Inhibition of the Bruton Tyrosine Kinase Pathway in B-Cell Lymphoproliferative Disorders.

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
PubMed Identifier: 26639348
author list: Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, Kipps TJ, Anderson MA, Brown JR, Gressick L, Wong S, Dunbar M, Zhu M, Desai MB, Cerri E, Heitner Enschede S, Humerickhouse RA, Wierda WG, Seymour JF
published in: The New England journal of medicine
information resource reference: Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2016 Jan 28; 374(4):311-22.
journal title abbreviation: N Engl J Med
publication date: 2015-12-06T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women.
PubMed Identifier: 21394499
author list: Comen E, Davids M, Kirchhoff T, Hudis C, Offit K, Robson M
published in: Breast cancer research and treatment
information resource reference: Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women. Breast Cancer Res Treat. 2011 Aug; 129(1):185-90.
journal title abbreviation: Breast Cancer Res Treat
publication date: 2011-03-11T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 876071
type: Authorship
author rank in publication: 9
linked author: Davids, Matthew
linked information resource: A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma.

A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma.
PubMed Identifier: 26729345
author list: Armand P, Redd R, Bsat J, Mayuram S, Giardino A, Fisher DC, LaCasce AS, Jacobson C, Davids MS, Brown JR, Weng L, Wilkins J, Faham M, Freedman AS, Joyce R, Jacobsen ED
published in: British journal of haematology
information resource reference: A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma. Br J Haematol. 2016 Apr; 173(1):89-95.
journal title abbreviation: Br J Haematol
publication date: 2016-01-05T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 876372
type: Authorship
author rank in publication: 23
linked author: Davids, Matthew
linked information resource: The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.
PubMed Identifier: 27070704
author list: Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM
published in: Cancer cell
information resource reference: The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586.
journal title abbreviation: Cancer Cell
publication date: 2016-04-11T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 882747
type: Authorship
author rank in publication: 25
linked author: Davids, Matthew
linked information resource: Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.

Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.
PubMed Identifier: 27199251
author list: Burger JA, Landau DA, Taylor-Weiner A, Bozic I, Zhang H, Sarosiek K, Wang L, Stewart C, Fan J, Hoellenriegel J, Sivina M, Dubuc AM, Fraser C, Han Y, Li S, Livak KJ, Zou L, Wan Y, Konoplev S, Sougnez C, Brown JR, Abruzzo LV, Carter SL, Keating MJ, Davids MS, Wierda WG, Cibulskis K, Zenz T, Werner L, Dal Cin P, Kharchencko P, Neuberg D, Kantarjian H, Lander E, Gabriel S, O'Brien S, Letai A, Weitz DA, Nowak MA, Getz G, Wu CJ
published in: Nature communications
information resource reference: Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun. 2016 05 20; 7:11589.
journal title abbreviation: Nat Commun
publication date: 2016-05-20T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 884746
type: Authorship
author rank in publication: 2
linked author: Davids, Matthew
linked information resource: New Agents to Treat Chronic Lymphocytic Leukemia.

New Agents to Treat Chronic Lymphocytic Leukemia.
PubMed Identifier: 27248631
author list: Roberts AW, Davids MS, Seymour JF
published in: The New England journal of medicine
information resource reference: New Agents to Treat Chronic Lymphocytic Leukemia. N Engl J Med. 2016 06 02; 374(22):2186-7.
journal title abbreviation: N Engl J Med
publication date: 2016-06-02T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 888229
type: Authorship
author rank in publication: 15
linked author: Davids, Matthew
linked information resource: The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.

The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.
PubMed Identifier: 27069256
author list: Anderson MA, Deng J, Seymour JF, Tam C, Kim SY, Fein J, Yu L, Brown JR, Westerman D, Si EG, Majewski IJ, Segal D, Heitner Enschede SL, Huang DC, Davids MS, Letai A, Roberts AW
published in: Blood
information resource reference: The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood. 2016 06 23; 127(25):3215-24.
journal title abbreviation: Blood
publication date: 2016-04-11T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Assistant Professor
sort order: 2
type: Faculty Rank

Associate Professor
sort order: 1
type: Faculty Rank

Fellow or Post Doc
sort order: 6
type: Faculty Rank

Full Professor
sort order: 0
type: Faculty Rank

Instructor
sort order: 4
type: Faculty Rank

Lecturer
sort order: 3
type: Faculty Rank

Other Faculty
sort order: 5
type: Faculty Rank

Authorship 891651
type: Authorship
author rank in publication: 6
linked author: Davids, Matthew
linked information resource: Imatinib mesylate (Gleevec?) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial.

Authorship 891460
type: Authorship
author rank in publication: 6
linked author: Davids, Matthew
linked information resource: Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity.

Authorship 891551
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: Ipilimumab for Patients with Relapse after Allogeneic Transplantation.

Ipilimumab for Patients with Relapse after Allogeneic Transplantation.
PubMed Identifier: 27410923
author list: Davids MS, Kim HT, Bachireddy P, Costello C, Liguori R, Savell A, Lukez AP, Avigan D, Chen YB, McSweeney P, LeBoeuf NR, Rooney MS, Bowden M, Zhou CW, Granter SR, Hornick JL, Rodig SJ, Hirakawa M, Severgnini M, Hodi FS, Wu CJ, Ho VT, Cutler C, Koreth J, Alyea EP, Antin JH, Armand P, Streicher H, Ball ED, Ritz J, Bashey A, Soiffer RJ
published in: The New England journal of medicine
information resource reference: Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med. 2016 Jul 14; 375(2):143-53.
journal title abbreviation: N Engl J Med
publication date: 2016-07-14T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Imatinib mesylate (Gleevec?) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial.
PubMed Identifier: 25152211
author list: Gordon J, Udeh U, Doobay K, Magro C, Wildman H, Davids M, Mersten JN, Huang WT, Lyman S, Crow MK, Spiera RF
published in: Clinical and experimental rheumatology
information resource reference: Imatinib mesylate (Gleevec?) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial. Clin Exp Rheumatol. 2014 Nov-Dec; 32(6 Suppl 86):S-189-93.
journal title abbreviation: Clin Exp Rheumatol
publication date: 2014-08-15T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity.
PubMed Identifier: 27247136
author list: Lampson BL, Kasar SN, Matos TR, Morgan EA, Rassenti L, Davids MS, Fisher DC, Freedman AS, Jacobson CA, Armand P, Abramson JS, Arnason JE, Kipps TJ, Fein J, Fernandes S, Hanna J, Ritz J, Kim HT, Brown JR
published in: Blood
information resource reference: Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016 07 14; 128(2):195-203.
journal title abbreviation: Blood
publication date: 2016-05-31T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 896388
type: Authorship
author rank in publication: 11
linked author: Davids, Matthew
linked information resource: Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis.

Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis.
PubMed Identifier: 27480113
author list: Pavlasova G, Borsky M, Seda V, Cerna K, Osickova J, Doubek M, Mayer J, Calogero R, Trbusek M, Pospisilova S, Davids MS, Kipps TJ, Brown JR, Mraz M
published in: Blood
information resource reference: Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis. Blood. 2016 09 22; 128(12):1609-13.
journal title abbreviation: Blood
publication date: 2016-08-01T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 916985
type: Authorship
author rank in publication: 2
linked author: Davids, Matthew
linked information resource: FISHing in the dark: How the combination of FISH and conventional karyotyping improves the diagnostic yield in CpG-stimulated chronic lymphocytic leukemia.

FISHing in the dark: How the combination of FISH and conventional karyotyping improves the diagnostic yield in CpG-stimulated chronic lymphocytic leukemia.
PubMed Identifier: 27341486
author list: Dubuc AM, Davids MS, Pulluqi M, Pulluqi O, Hoang K, Hernandez-Sánchez JM, Schlich C, Hernández-Rivas JM, Brown JR, Dal Cin P
published in: American journal of hematology
information resource reference: FISHing in the dark: How the combination of FISH and conventional karyotyping improves the diagnostic yield in CpG-stimulated chronic lymphocytic leukemia. Am J Hematol. 2016 10; 91(10):978-83.
journal title abbreviation: Am J Hematol
publication date: 2016-07-22T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 94876
type: Authorship
author rank in publication: 5
linked author: Davids, Matthew
linked information resource: BCL2 suppresses PARP1 function and nonapoptotic cell death.

Authorship 928095
type: Authorship
author rank in publication: 9
linked author: Davids, Matthew
linked information resource: Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103.

Authorship 922611
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: Cell Trafficking in Chronic Lymphocytic Leukemia.

Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103.
PubMed Identifier: 27697771
author list: Ujjani CS, Jung SH, Pitcher B, Martin P, Park SI, Blum KA, Smith SM, Czuczman M, Davids MS, Levine E, Lewis LD, Smith SE, Bartlett NL, Leonard JP, Cheson BD
published in: Blood
information resource reference: Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103. Blood. 2016 11 24; 128(21):2510-2516.
journal title abbreviation: Blood
publication date: 2016-10-03T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Cell Trafficking in Chronic Lymphocytic Leukemia.
PubMed Identifier: 22844583
author list: Davids MS, Burger JA
published in: Open journal of hematology
information resource reference: Cell Trafficking in Chronic Lymphocytic Leukemia. Open J Hematol. 2012; 3(S1).
journal title abbreviation: Open J Hematol
publication date: 2012-02-21T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax.
PubMed Identifier: 27986708
author list: Montero J, Stephansky J, Cai T, Griffin GK, Cabal-Hierro L, Togami K, Hogdal LJ, Galinsky I, Morgan EA, Aster JC, Davids MS, LeBoeuf NR, Stone RM, Konopleva M, Pemmaraju N, Letai A, Lane AA
published in: Cancer discovery
information resource reference: Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax. Cancer Discov. 2017 02; 7(2):156-164.
journal title abbreviation: Cancer Discov
publication date: 2016-12-16T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 941129
type: Authorship
author rank in publication: 11
linked author: Davids, Matthew
linked information resource: Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax.

Authorship 948202
type: Authorship
author rank in publication: 17
linked author: Davids, Matthew
linked information resource: Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.

Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.
PubMed Identifier: 28034071
author list: Herrera AF, Mei M, Low L, Kim HT, Griffin GK, Song JY, Merryman RW, Bedell V, Pak C, Sun H, Paris T, Stiller T, Brown JR, Budde LE, Chan WC, Chen R, Davids MS, Freedman AS, Fisher DC, Jacobsen ED, Jacobson CA, LaCasce AS, Murata-Collins J, Nademanee AP, Palmer JM, Pihan GA, Pillai R, Popplewell L, Siddiqi T, Sohani AR, Zain J, Rosen ST, Kwak LW, Weinstock DM, Forman SJ, Weisenburger DD, Kim Y, Rodig SJ, Krishnan A, Armand P
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. J Clin Oncol. 2017 Jan; 35(1):24-31.
journal title abbreviation: J Clin Oncol
publication date: 2016-10-24T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 950410
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.
PubMed Identifier: 28095146
author list: Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, Puvvada S, Kipps TJ, Anderson MA, Salem AH, Dunbar M, Zhu M, Peale F, Ross JA, Gressick L, Desai M, Kim SY, Verdugo M, Humerickhouse RA, Gordon GB, Gerecitano JF
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. J Clin Oncol. 2017 Mar 10; 35(8):826-833.
journal title abbreviation: J Clin Oncol
publication date: 2017-01-17T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 951913
type: Authorship
author rank in publication: 2
linked author: Davids, Matthew
linked information resource: The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.

Authorship 952821
type: Authorship
author rank in publication: 6
linked author: Davids, Matthew
linked information resource: Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.

Authorship 952991
type: Authorship
author rank in publication: 6
linked author: Davids, Matthew
linked information resource: Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.

Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
PubMed Identifier: 28111464
author list: Deng J, Isik E, Fernandes SM, Brown JR, Letai A, Davids MS
published in: Leukemia
information resource reference: Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia. Leukemia. 2017 10; 31(10):2075-2084.
journal title abbreviation: Leukemia
publication date: 2017-01-23T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
PubMed Identifier: 28089635
author list: Seymour JF, Ma S, Brander DM, Choi MY, Barrientos J, Davids MS, Anderson MA, Beaven AW, Rosen ST, Tam CS, Prine B, Agarwal SK, Munasinghe W, Zhu M, Lash LL, Desai M, Cerri E, Verdugo M, Kim SY, Humerickhouse RA, Gordon GB, Kipps TJ, Roberts AW
published in: The Lancet. Oncology
information resource reference: Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol. 2017 Feb; 18(2):230-240.
journal title abbreviation: Lancet Oncol
publication date: 2017-01-13T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.
PubMed Identifier: 28116634
author list: Lampson BL, Davids MS
published in: Current hematologic malignancy reports
information resource reference: The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia. Curr Hematol Malig Rep. 2017 02; 12(1):11-19.
journal title abbreviation: Curr Hematol Malig Rep
publication date: 2017-02-01T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 965371
type: Authorship
author rank in publication: 2
linked author: Davids, Matthew
linked information resource: Prevalence of BRCA1 and BRCA2 mutations in Jewish women with triple negative breast cancer.

Authorship 962195
type: Authorship
author rank in publication: 23
linked author: Davids, Matthew
linked information resource: The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.
PubMed Identifier: 27479034
author list: Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM
published in: Cancer cell
information resource reference: The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183.
journal title abbreviation: Cancer Cell
publication date: 2016-07-11T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Prevalence of BRCA1 and BRCA2 mutations in Jewish women with triple negative breast cancer.
PubMed Identifier: 27951266
author list: Comen EA, Davids M, Kirchhoff T, Balistreri L, Hansen J, Kosarin K, Offit K, Robson ME
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Prevalence of BRCA1 and BRCA2 mutations in Jewish women with triple negative breast cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):22002.
journal title abbreviation: J Clin Oncol
publication date: 2008-05-20T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 971340
type: Authorship
author rank in publication: 7
linked author: Davids, Matthew
linked information resource: Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States.

Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States.
PubMed Identifier: 28302090
author list: Nabhan C, Mato A, Flowers CR, Grinblatt DL, Lamanna N, Weiss MA, Davids MS, Swern AS, Bhushan S, Sullivan K, Flick ED, Kiselev P, Sharman JP
published in: BMC cancer
information resource reference: Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States. BMC Cancer. 2017 03 16; 17(1):198.
journal title abbreviation: BMC Cancer
publication date: 2017-03-16T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

STK25 is a candidate gene for pseudopseudohypoparathyroidism.
PubMed Identifier: 11543625
author list: Davids MS, Crawford E, Weremowicz S, Morton CC, Copeland NG, Gilbert DJ, Jenkins NA, Phelan MC, Comb MJ, Melnick MB
published in: Genomics
information resource reference: STK25 is a candidate gene for pseudopseudohypoparathyroidism. Genomics. 2001 Sep; 77(1-2):2-4.
journal title abbreviation: Genomics
publication date: 2001-09-01T00:00:00
year: 2001
type: Academic Article
type: Article
type: Document
type: Information Resource

Immune-related fulminant myocarditis in a patient receiving ipilimumab therapy for relapsed chronic myelomonocytic leukaemia.
PubMed Identifier: 28485549
author list: Berg DD, Vaduganathan M, Nohria A, Davids MS, Alyea EP, Torre M, Padera RF
published in: European journal of heart failure
information resource reference: Immune-related fulminant myocarditis in a patient receiving ipilimumab therapy for relapsed chronic myelomonocytic leukaemia. Eur J Heart Fail. 2017 05; 19(5):682-685.
journal title abbreviation: Eur J Heart Fail
publication date: 2017-05-01T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 983529
type: Authorship
author rank in publication: 4
linked author: Davids, Matthew
linked information resource: Immune-related fulminant myocarditis in a patient receiving ipilimumab therapy for relapsed chronic myelomonocytic leukaemia.

Authorship 981496
type: Authorship
author rank in publication: 2
linked author: Davids, Matthew
linked information resource: Venetoclax for the treatment of patients with chronic lymphocytic leukemia.

Authorship 983097
type: Authorship
author rank in publication: 4
linked author: Davids, Matthew
linked information resource: A complex case of ibrutinib treatment for a CLL patient on haemodialysis.

A complex case of ibrutinib treatment for a CLL patient on haemodialysis.
PubMed Identifier: 28508526
author list: Aw A, Hellman JM, Birner A, Davids MS
published in: British journal of haematology
information resource reference: A complex case of ibrutinib treatment for a CLL patient on haemodialysis. Br J Haematol. 2018 06; 181(6):854-857.
journal title abbreviation: Br J Haematol
publication date: 2017-05-16T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Venetoclax for the treatment of patients with chronic lymphocytic leukemia.
PubMed Identifier: 28492339
author list: Crombie J, Davids MS
published in: Future oncology (London, England)
information resource reference: Venetoclax for the treatment of patients with chronic lymphocytic leukemia. Future Oncol. 2017 Jun; 13(14):1223-1232.
journal title abbreviation: Future Oncol
publication date: 2017-05-11T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 987105
type: Authorship
author rank in publication: 2
linked author: Davids, Matthew
linked information resource: IGHV mutational status testing in chronic lymphocytic leukemia.

IGHV mutational status testing in chronic lymphocytic leukemia.
PubMed Identifier: 28589701
author list: Crombie J, Davids MS
published in: American journal of hematology
information resource reference: IGHV mutational status testing in chronic lymphocytic leukemia. Am J Hematol. 2017 Dec; 92(12):1393-1397.
journal title abbreviation: Am J Hematol
publication date: 2017-07-29T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Ryan, Christine
eCommons Login: CR183
first name: Christine
last name: Ryan
full name: Christine Ryan, M.D.
has faculty rank: Instructor
Person ID: 159985
person in primary position: Instructor in Medicine
type: Agent
type: Person
preferred title: Instructor in Medicine

Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era.
PubMed Identifier: 23278720
author list: Armand P, Welch S, Kim HT, LaCasce AS, Jacobsen ED, Davids MS, Jacobson C, Fisher DC, Brown JR, Coughlin E, Freedman AS, Chen YB
published in: British journal of haematology
information resource reference: Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era. Br J Haematol. 2013 Mar; 160(5):608-17.
journal title abbreviation: Br J Haematol
publication date: 2012-12-29T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

450 Brookline Ave
type: Address
address line 1: Dana-Farber Cancer Institute
address line 2: Mayer 224
address line 3: 450 Brookline Ave
city: Boston
postal code: 02215
state or province: MA

Targeting the B-cell lymphoma/leukemia 2 family in cancer.
PubMed Identifier: 22649144
author list: Davids MS, Letai A
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Targeting the B-cell lymphoma/leukemia 2 family in cancer. J Clin Oncol. 2012 Sep 01; 30(25):3127-35.
journal title abbreviation: J Clin Oncol
publication date: 2012-05-29T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1006149
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: Targeting BCL-2 in B-cell lymphomas.

Targeting BCL-2 in B-cell lymphomas.
PubMed Identifier: 28724540
author list: Davids MS
published in: Blood
information resource reference: Targeting BCL-2 in B-cell lymphomas. Blood. 2017 08 31; 130(9):1081-1088.
journal title abbreviation: Blood
publication date: 2017-07-19T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1031143
type: Authorship
author rank in publication: 1
linked author: Davids, Matthew
linked information resource: How should we sequence and combine novel therapies in CLL?

Authorship 1034942
type: Authorship
author rank in publication: 2
linked author: Davids, Matthew
linked information resource: Safety profiles of novel agent therapies in CLL.

Authorship 1030982
type: Authorship
author rank in publication: 4
linked author: Davids, Matthew
linked information resource: Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.

Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.
PubMed Identifier: 29246803
author list: Jones JA, Mato AR, Wierda WG, Davids MS, Choi M, Cheson BD, Furman RR, Lamanna N, Barr PM, Zhou L, Chyla B, Salem AH, Verdugo M, Humerickhouse RA, Potluri J, Coutre S, Woyach J, Byrd JC
published in: The Lancet. Oncology
information resource reference: Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018 01; 19(1):65-75.
journal title abbreviation: Lancet Oncol
publication date: 2017-12-12T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

How should we sequence and combine novel therapies in CLL?
PubMed Identifier: 29222277
author list: Davids MS
published in: Hematology. American Society of Hematology. Education Program
information resource reference: How should we sequence and combine novel therapies in CLL? Hematology Am Soc Hematol Educ Program. 2017 12 08; 2017(1):346-353.
journal title abbreviation: Hematology Am Soc Hematol Educ Program
publication date: 2017-12-08T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Safety profiles of novel agent therapies in CLL.
PubMed Identifier: 29222278
author list: Ahn IE, Davids MS
published in: Hematology. American Society of Hematology. Education Program
information resource reference: Safety profiles of novel agent therapies in CLL. Hematology Am Soc Hematol Educ Program. 2017 12 08; 2017(1):354-357.
journal title abbreviation: Hematology Am Soc Hematol Educ Program
publication date: 2017-12-08T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic Merkel cell carcinoma.
PubMed Identifier: 19564526
author list: Davids MS, Davids M, Charlton A, Ng SS, Chong ML, Laubscher K, Dar M, Hodge J, Soong R, Goh BC
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic Merkel cell carcinoma. J Clin Oncol. 2009 Sep 10; 27(26):e97-100.
journal title abbreviation: J Clin Oncol
publication date: 2009-06-29T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Assessing surge capacity for radiation victims with marrow toxicity.
PubMed Identifier: 20399880
author list: Davids MS, Case C, Hornung R, Chao NJ, Chute JP, Coleman CN, Weisdorf D, Confer DL, Weinstock DM
published in: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
information resource reference: Assessing surge capacity for radiation victims with marrow toxicity. Biol Blood Marrow Transplant. 2010 Oct; 16(10):1436-41.
journal title abbreviation: Biol Blood Marrow Transplant
publication date: 2010-04-24T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Medical management of radiation victims in the United States.
PubMed Identifier: 20445390
author list: Davids MS, Case C, Confer DL, Weisdorf DJ, Weinstock DM
published in: Health physics
information resource reference: Medical management of radiation victims in the United States. Health Phys. 2010 Jun; 98(6):833-7.
journal title abbreviation: Health Phys
publication date: 2010-06-01T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

BCL2 suppresses PARP1 function and nonapoptotic cell death.
PubMed Identifier: 22689920
author list: Dutta C, Day T, Kopp N, van Bodegom D, Davids MS, Ryan J, Bird L, Kommajosyula N, Weigert O, Yoda A, Fung H, Brown JR, Shapiro GI, Letai A, Weinstock DM
published in: Cancer research
information resource reference: BCL2 suppresses PARP1 function and nonapoptotic cell death. Cancer Res. 2012 Aug 15; 72(16):4193-203.
journal title abbreviation: Cancer Res
publication date: 2012-06-11T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1036295
type: Authorship
author rank in publication: 3
linked author: Davids, Matthew
linked information resource: Early progression of disease as a predictor of survival in chronic lymphocytic leukemia.

Early progression of disease as a predictor of survival in chronic lymphocytic leukemia.
PubMed Identifier: 29296893
author list: Ahn IE, Farber CM, Davids MS, Grinblatt DL, Kay NE, Lamanna N, Mato A, Nabhan C, Kiselev P, Swern AS, Flick ED, Sullivan K, Sharman JP, Flowers CR
published in: Blood advances
information resource reference: Early progression of disease as a predictor of survival in chronic lymphocytic leukemia. Blood Adv. 2017 Nov 28; 1(25):2433-2443.
journal title abbreviation: Blood Adv
publication date: 2017-11-28T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1037760
type: Authorship
author rank in publication: 15
linked author: Davids, Matthew
linked information resource: Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy.

Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy.
PubMed Identifier: 29305552
author list: Coutre S, Choi M, Furman RR, Eradat H, Heffner L, Jones JA, Chyla B, Zhou L, Agarwal S, Waskiewicz T, Verdugo M, Humerickhouse RA, Potluri J, Wierda WG, Davids MS
published in: Blood
information resource reference: Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. Blood. 2018 04 12; 131(15):1704-1711.
journal title abbreviation: Blood
publication date: 2018-01-05T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Serum free light chain analysis.
PubMed Identifier: 20721885
author list: Davids MS, Murali MR, Kuter DJ
published in: American journal of hematology
information resource reference: Serum free light chain analysis. Am J Hematol. 2010 Oct; 85(10):787-90.
journal title abbreviation: Am J Hematol
publication date: 2010-10-01T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Targeting the B cell receptor pathway in chronic lymphocytic leukemia.
PubMed Identifier: 22616724
author list: Davids MS, Brown JR
published in: Leukemia & lymphoma
information resource reference: Targeting the B cell receptor pathway in chronic lymphocytic leukemia. Leuk Lymphoma. 2012 Dec; 53(12):2362-70.
journal title abbreviation: Leuk Lymphoma
publication date: 2012-12-01T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1038845
type: Authorship
author rank in publication: 9
linked author: Davids, Matthew
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/96716190

https://connects.catalyst.harvard.edu/Profiles/profile/96716190
PubMed Identifier: 29352719
author list: Mato A, Nabhan C, Kay NE, Lamanna N, Kipps TJ, Grinblatt DL, Flowers CR, Farber CM, Davids MS, Kiselev P, Swern AS, Bhushan S, Sullivan K, Flick ED, Sharman JP
published in: Clinical lymphoma, myeloma & leukemia
information resource reference: Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry. Clin Lymphoma Myeloma Leuk. 2018 02; 18(2):114-124.e2.
journal title abbreviation: Clin Lymphoma Myeloma Leuk
publication date: 2017-12-06T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry.

Authorship 1041139
type: Authorship
author rank in publication: 2
linked author: Davids, Matthew
linked information resource: Tyrosine kinase inhibitors and immune checkpoint blockade in allogeneic hematopoietic cell transplantation.

Tyrosine kinase inhibitors and immune checkpoint blockade in allogeneic hematopoietic cell transplantation.
PubMed Identifier: 29358177
author list: Soiffer RJ, Davids MS, Chen YB
published in: Blood
information resource reference: Tyrosine kinase inhibitors and immune checkpoint blockade in allogeneic hematopoietic cell transplantation. Blood. 2018 03 08; 131(10):1073-1080.
journal title abbreviation: Blood
publication date: 2018-01-22T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

ABT-199: taking dead aim at BCL-2.
PubMed Identifier: 23410971
author list: Davids MS, Letai A
published in: Cancer cell
information resource reference: ABT-199: taking dead aim at BCL-2. Cancer Cell. 2013 Feb 11; 23(2):139-41.
journal title abbreviation: Cancer Cell
publication date: 2013-02-11T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource